Docstoc
EXCLUSIVE OFFER FOR DOCSTOC USERS
Try the all-new QuickBooks Online for FREE.  No credit card required.

GenVec_Pipeline

Document Sample
GenVec_Pipeline Powered By Docstoc
					                                                                                GENVEC INC


                                                                               Pipeline Report

 Comprehensive coverage of GENVEC INC's pipeline of products, including both summary information and
                                                                   detailed individual product records.




                                                                     Publication Date: January 04,2010




Life Science Analytics
www.lifescienceanalytics.com
800 James Avenue
Scranton, PA 18510
ABOUT LIFE SCIENCE ANALYTICS



ABOUT Life Science Analytics

This report has been prepared by Life Science Analytics (LSA) analysts using data from MedTRACK, a
proven competitive intelligence source for the life sciences.

Life Science Analytics is a leading provider of global biomedical corporate intelligence, specializing in
comprehensive pipeline and financial information. Business development officers, librarians, and executives
of biomedical companies, as well as vendors and consultants who serve those companies, turn to LSA for
their corporate intelligence projects.

LSA's Report Center tracks over 2500 pharmaceutical, biotechnology and biomedical companies worldwide.
With report offerings in Deals & Alliances, Financial, Therapy Area Pipeline, Competitor, and Company
information, Life Science Analytics has developed a reputation for authoritative research through an
unbiased, accurate and independent approach to company analysis.

LSA's premier product, MedTRACK, is the most comprehensive database of public and private companies
available. MedTRACK tracks pipeline, financial, competitive product, deal, technology, and patent
information on more than 16,000 biomedical companies worldwide. Drawing from a wealth of public and
proprietary sources, users have the ability to search for and screen comprehensive company information,
drug targets and other scientific product details, worldwide patent information, epidemiology reports, product
sales, R&D spending, news, SEC filings, and more.

In addition to MedTRACK, LSA offers standalone products, MedTRACK Deals & Alliances and MedTRACK
Venture Finance, that provide comprehensive coverage of over 46,541 deals and 12,279 venture rounds in
the biomedical industries, making them industry leaders in breadth and depth of coverage.




Disclaimer
The information contained herein is based on sources believed to be reliable but is neither all-inclusive nor
guaranteed by Life Science Analytics (LSA). Opinions, if any, reflect the judgment of LSA at this time and
are subject to change. LSA does not undertake to advise you of changes in their opinion or information.
Many of the companies LSA evaluates are emerging growth companies whose securities typically involve a
higher degree of risk and more volatility than the securities of more established companies. The securities
discussed in the reports included in LSA's Database may be unsuitable for investors depending on their
specific investment objectives, financial situation and needs. No report included in the LSA Database is a
recommendation that any particular investor should purchase or sell any particular security in any amount or
at all, and is not a solicitation of any offer to purchase or sell from or to any particular investor. For additional
information that may be available on the securities mentioned, please contact Life Science Analytics.




GenVec Inc - Pipeline Report                                                                                        2

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Table of Contents
Business Summary ......................................................................................................................................... 4

Financials ........................................................................................................................................................ 5

Product Glance................................................................................................................................................ 6
   Products by Phase of Development ............................................................................................................ 6
   Products by Disease Hub Classification...................................................................................................... 7
   Products by Indication ................................................................................................................................. 8

Product Pipeline ............................................................................................................................................ 14

Product Details .............................................................................................................................................. 16

Recent Updates............................................................................................................................................. 66
   Company Announcements ........................................................................................................................ 66
   Deals & Alliances....................................................................................................................................... 67
   Regulatory ................................................................................................................................................. 68

Clinical Trial Classification and Product Counts ............................................................................................ 69




GenVec Inc - Pipeline Report                                                                                                                                       3

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Business Summary
GenVec Inc          (NasdaqGM) Symbol : GNVC

Headquarters
65 West Watkins Mill Road,
Gaithersburg,
Maryland      20878
Phone 240-632-0740
www.genvec.com

       GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines.
        GenVec's proprietary adenovector technology to develop vaccines for infectious diseases including
HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Its lead program,
TNFerade(TM) represents a novel approach to treating cancer in combination with radiation and/or
chemotherapy by introducing tumor necrosis factor-alpha (TNF-alpha). The company is developing
TNFerade(TM) Biologic for use in combination with radiation and/or chemotherapy for the treatment of
various cancers.
        GenVec's TherAtoh Atonal therapy is a product concept to restore hearing or balance function
through the regeneration of critical cells of the inner ear. The ATOH protein results in the formation of new
inner ear sensory hair cells, and the restoration of hearing and balance function.
        GenVec has collaborations with National Institutes of Health, Cobra Biomanufacturing Plc, Naval
Medical Research Center, U.S. Department of Homeland Security, etc.
* Source: MedTRACK




GenVec Inc - Pipeline Report                                                                                    4

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Financials

Symbol                                                            GNVC
Exchange                                                          NasdaqGM
Currency                                                          US Dollar
Close ( 12/31/2009)                                               1.2
Volume (12/31/2009)                                               1,606M
Weekly High                                                       1.200
Weekly Low                                                        1.030
Weekly Close                                                      1.080
52 Week High                                                      1.220
52 Week Low                                                       0.330
Shares Outstanding                                                106M
Market Cap                                                        127.603M
Enterprise Value                                                  113.373M
Dividend Yield                                                    0.000
P/E Ratio                                                         -3.488
Price to Book Value                                               7.063
Price to Sales                                                    5.163
EV/ Sales                                                         8.200
EV/ EBITDA                                                        -3.576
Cash On Hand                                                      14.230M
Years In Cash                                                     0.695
* Source: MedTRACK




GenVec Inc - Pipeline Report                                                  5

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Product Glance
Products by Phase of Development

Trial Phase                                                       No. of Products
Unknown/Research                                                  2
Pre Clinical                                                      4
Clinical Trial Phase I                                            2
Clinical Trial Phase II                                           7
Clinical Trial Phase III                                          1
Discontinued                                                      4
Failed                                                            1
* Source: MedTRACK


Products by Phase of Development Chart




GenVec Inc - Pipeline Report                                                        6

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Products by Disease Hub Classification

Disease Hub                                                       No. of Products
Cancer                                                            7
Cardiovascular and Circulatory System                             3
Infections                                                        7
Miscellaneous                                                     1
Ophthalmology and Optometry                                       1
Respiratory and Pulmonary System                                  2
* Source: MedTRACK


Products by Disease Hub Classification Chart




GenVec Inc - Pipeline Report                                                        7

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Products by Indication

Cancer

Indication                                                        No. of Products
Colorectal Cancer                                                 1
Esophageal Cancer                                                 1
Head and Neck Cancer                                              2
Melanoma                                                          1
Pancreatic Cancer                                                 1
Sarcoma                                                           1
* Source: MedTRACK


Cancer Chart




GenVec Inc - Pipeline Report                                                        8

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Cardiovascular and Circulatory System

Indication                                                        No. of Products
Congestive Heart Failure                                          1
Coronary Artery Disease                                           1
Peripheral Vascular Disease                                       1
* Source: MedTRACK


Cardiovascular and Circulatory System Chart




GenVec Inc - Pipeline Report                                                        9

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Infections

Indication                                                        No. of Products
AIDS/HIV                                                          3
Herpes Simplex Virus Infection                                    1
Influenza                                                         1
Malaria                                                           2
* Source: MedTRACK


Infections Chart




GenVec Inc - Pipeline Report                                                        10

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Miscellaneous

Indication                                                        No. of Products
Hearing Loss                                                      1
* Source: MedTRACK


Miscellaneous Chart




GenVec Inc - Pipeline Report                                                        11

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Ophthalmology and Optometry

Indication                                                        No. of Products
Macular Degeneration                                              1
* Source: MedTRACK


Ophthalmology and Optometry Chart




GenVec Inc - Pipeline Report                                                        12

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Respiratory and Pulmonary System

Indication                                                        No. of Products
Respiratory Syncytial Virus (RSV) Infection                       1
Severe Acute Respiratory Syndrome (SARS)                          1
* Source: MedTRACK


Respiratory and Pulmonary System Chart




GenVec Inc - Pipeline Report                                                        13

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Product Pipeline

#                                    Products                     Condition Treated          Trial Phase
1                                    Herpes Simplex Virus         Herpes Simplex Virus       NA
                                     Type 2 Vaccine               Infection (Herpes
                                     GENVEC                       Simplex Virus Type 2
                                                                  Infection)
2                                    SARS Vaccine GENVEC          Severe Acute               NA
                                                                  Respiratory Syndrome
                                                                  (SARS)
3                                    5 Antigen Vaccine            Malaria                    PC
                                     GENVEC
4                                    Influenza Vaccine            Influenza (Seasonal and    PC
                                     GENVEC                       Pandemic Flu)
5                                    Respiratory Syncytial        Respiratory Syncytial      PC
                                     Virus Vaccine GENVEC         Virus (RSV) Infection
6                                    TherAtoh                     Hearing Loss               PC
7                                    Ad35HIV-EnvA Vaccine         AIDS/HIV (HIV-1            I
                                                                  Infection)
8                                    AdPEDF                       Macular Degeneration       I
                                                                  (Wet Age-Related
                                                                  Macular Degeneration)
9                                    Malaria Vaccine              Malaria                    II
                                     GENVEC
10                                   rAd5 HIV- 1 Vaccine          AIDS/HIV (HIV Infection)   II
11                                   rAd5 HIV- 1 Vaccine with     AIDS/HIV                   II
                                     Plasmid DNA Vaccine
                                     Prime
12                                   TNFerade with                Colorectal Cancer          II
                                     Capecitabine and             (Locally Advanced
                                     Radiotherapy                 Rectal Cancer)
13                                   TNFerade with                Head and Neck Cancer       II
                                     Cetuximab,                   (Head and Neck Cancer
                                     Radiotherapy (First Line)    in Elderly or Frail
                                                                  Patients)
14                                   TNFerade with                Head and Neck Cancer       II
                                     Concomitant                  (Unresectable, Recurrent
                                     Radiotherapy and             Head and Neck Cancer
                                     Chemotherapy (Second         (Second Line Therapy))
                                     Line)
15                                   TNFerade with                Esophageal Cancer          II
                                     Radiotherapy and             (Locally Advanced
                                     Chemotherapy (First          Resectable Esophageal
                                     Line)                        Cancer)
16                                   TNFerade with                Pancreatic Cancer          III
                                     Radiotherapy and             (Unresectable Locally

GenVec Inc - Pipeline Report                                                                               14

© Life Science Analytics, Inc. 2010 (published January 04,2010)
#                                    Products                     Condition Treated          Trial Phase
                                     Chemotherapy (First          Advanced Pancreatic
                                     Line)                        Cancer (First Line
                                                                  Therapy))
17                                   BioBypass                    Coronary Artery Disease    D
18                                   Myoblast Cell                Congestive Heart Failure   D
                                     Transplantation Therapy
                                     GENVEC
19                                   TNFerade                     Melanoma                   D
20                                   TNFerade                     Sarcoma (Soft Tissue       D
                                                                  Sarcoma)
21                                   BioBypass                    Peripheral Vascular        F
                                                                  Disease (Peripheral
                                                                  Arterial Disease)
* Source: MedTRACK




GenVec Inc - Pipeline Report                                                                               15

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Product Details

1 . Herpes Simplex Virus Type 2 Vaccine GENVEC
Disease Hub                                    Infections
Therapeutic Indication                         Herpes Simplex Virus Infection (Herpes Simplex
                                               Virus Type 2 Infection)
Current Trial                                  NA
Description                                    Herpes Simplex Virus Type 2 Vaccine is based on
                                               adenovector technology. Adenovector delivers a
                                               gene that causes production of antigen, which then
                                               stimulates the desired immune reaction by the body.
                                               Herpes Simplex Virus Type 2 Vaccine is being
                                               developed as a prophylactic and therapeutic vaccine
                                               against the infections due to HSV-2 (Herpes Simplex
                                               Virus Type 2) virus.
Mechanism of Action                            Not Applicable
Mode of Action                                 Immunostimulant;Prophylactic Vaccine;Therapeutic
                                               Vaccine
Classification                                 1) Biological> Immunologic and Biological Factors>
                                               > Biological Products> > > Vaccines> > > > Viral
                                               Vaccines

Trial Details                                                     Presently it is in developmental stage
Last Updated                                                      8/18/2009
2 . SARS Vaccine GENVEC
Product Type                                    Investigational drugs
Disease Hub                                     Respiratory and Pulmonary System
Therapeutic Indication                          Severe Acute Respiratory Syndrome (SARS)
Current Trial                                   NA
Description                                     SARS vaccine is based on adenovector technology.
                                                Adenovector delivers a gene that causes production
                                                of antigen, which then stimulates the desired
                                                immune reaction by the body. SARS vaccine is
                                                being developed for the treatment of severe acute
                                                respiratory syndrome.
Mechanism of Action                             Not Applicable
Mode of Action                                  Immunostimulant;Therapeutic Vaccine
                    severe acute respiratory syndrome gene (recombinant)
Classification                                  1) Biological> Immunologic and Biological Factors>
                                                > Biological Products> > > Vaccines> > > > Viral
                                                Vaccines

Trial Details                                                     In December 2001, the Vaccine Research Center
                                                                  (VRC) at the National Institute of Allergy and
                                                                  Infectious Diseases of the National Institutes of
                                                                  Health (NIAID) selected the Company to collaborate

GenVec Inc - Pipeline Report                                                                                       16

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  in the development of a SARS vaccine candidate.
                                                                          Source: SEC File: 10-K (3/17/2008)
Last Updated                                                      8/18/2009
3 . 5 Antigen Vaccine GENVEC
Disease Hub                                                       Infections
Therapeutic Indication                                            Malaria
Current Trial                                                     PC
Description                                                       5-Antigen Vaccine is being developed against
                                                                  malaria.
Mechanism of Action                                               Not Applicable
Mode of Action                                                    Immunostimulant
Trial Details                                                     Additionally, a 5-antigen vaccine is being developed
                                                                  in collaboration with PATH's Malaria Vaccine
                                                                  Initiative (MVI) and the NMRC. This vaccine is in
                                                                  preclinical testing.
                                                                           Source: SEC File: 10-K (2008)
Last Updated                                                      8/24/2009
Partnering Details                                                3/31/2004 -- Update on July 27, 2009:
                                                                           GenVec, Inc. has expanded its existing
                                                                  contract with the PATH Malaria Vaccine Initiative
                                                                  (MVI), to support the development of vaccines to
                                                                  fight malaria through MVI and the United States
                                                                  Agency for International Development (USAID)
                                                                  funding. All the partners involved in this transaction
                                                                  are based in the US.
                                                                            GenVec is a biopharmaceutical company
                                                                  engaged in developing novel therapeutic drugs and
                                                                  vaccines, while MVI is a non-profit organization
                                                                  engaged in accelerating the development of malaria
                                                                  vaccines.
                                                                           The contract is valued at approximately $2
                                                                  million, would continue a collaboration that began in
                                                                  2004 and will initially support preclinical feasibility
                                                                  studies of novel adenovirus-based vaccines. Based
                                                                  on the results of the feasibility studies, GenVec,
                                                                  MVI, and USAID would contemplate preclinical and
                                                                  clinical development of these vaccines.
                                                                           Update on May 1, 2007:
                                                                           GenVec has amended and extended its
                                                                  existing collaborative research, development, and
                                                                  supply agreement (CRADS) with MVI. This
                                                                  amendment includes up to $0.75 million in additional
                                                                  funding through the end of 2007, to continue
                                                                  advancing a new multivalent malaria vaccine
                                                                  towards clinical evaluation.
                                                                           MVI has amended the original agreement to


GenVec Inc - Pipeline Report                                                                                           17

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  provide sufficient funding for GenVec and its
                                                                  collaborator, NMRC, to complete the last steps in
                                                                  pre-clinical development prior to the production of
                                                                  cGMP materials that will be required for human
                                                                  clinical evaluation.
                                                                           Announcement (March 31, 2004):
                                                                           GenVec, MVI and NMRC have entered into
                                                                  an agreement to enable scientists to assess whether
                                                                  five malaria antigens, (or) proteins, can generate
                                                                  strong immune responses alone or in combination.
                                                                           Under a two year CRADS, MVI would
                                                                  provide GenVec up to $2.5 million for the production
                                                                  and evaluation of adenovirus vectors containing
                                                                  genes for up to five malaria antigens. GenVec'
                                                                  proprietary adenovector technology uses a
                                                                  replication deficient adenovector to deliver the genes
                                                                  to cause the production of beneficial antigens or
                                                                  proteins.
                                                                           Under a separate collaborative research and
                                                                  development agreement between GenVec and
                                                                  NMRC, NMRC scientists would provide GenVec with
                                                                  optimized malaria genes to be used in the
                                                                  adenovector vaccines. NMRC would then compare
                                                                  the effects of these vaccines alone and in
                                                                  combination in animal models.
4 . Influenza Vaccine GENVEC
Product Type                                                      Generic
Disease Hub                                                       Infections
Therapeutic Indication                                            Influenza (Seasonal and Pandemic Flu)
Current Trial                                                     PC
Description                                                       Influenza Vaccine is designed to generate a broad
                                                                  spectrum of immune responses including
                                                                  neutralizing antibodies and cytolytic T cell immunity.
                                                                  Influenza vaccine is being developed using
                                                                  adenovector technology for the treatment of
                                                                  seasonal and pandemic flu.
Technology Description                                            Virus-Like Particles (VLPs) Technology
Mechanism of Action                                               Not Applicable
Mode of Action                                                    Immunostimulant;Therapeutic Vaccine
Classification                                                    1) Biological> Immunologic and Biological Factors>
                                                                  > Biological Products> > > Vaccines> > > > Viral
                                                                  Vaccines

Trial Details                                                     GenVec has collaborated with the VRC to develop
                                                                  and supply potential vaccine candidates for
                                                                  seasonal and pandemic flu. Initial candidates are in


GenVec Inc - Pipeline Report                                                                                           18

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  preclinical testing.
                                                                           Source: SEC File: 10-K (2008)
                                                                           In April 2003, collaboration with Vaccine
                                                                  Research Center (VRC) at the National Institute of
                                                                  Allergy and Iqnfectious Diseases of the National
                                                                  Institutes of Health (NIAID) was expanded to include
                                                                  the development of a SARS vaccine candidate and
                                                                  in February 2006 it was expanded to include an
                                                                  influenza vaccine candidate.
                                                                           Source: SEC File: 10-K (2008)
                                                                           February 9, 2006 GenVec, Inc. announced
                                                                  that it has received initial funding of USD300,000 to
                                                                  begin preliminary vector development with the
                                                                  Vaccine Research Center (VRC) of the National
                                                                  Institute of Allergy and Infectious Diseases (NIAID),
                                                                  National Institutes of Health, in preparation for the
                                                                  manufacture of clinical grade adenovector-based
                                                                  influenza vaccines. This initial seasonal and
                                                                  pandemic flu vaccine research effort was agreed to
                                                                  through an extension of the USD50 million
                                                                  subcontract issued and managed by AIC-Frederick
                                                                  under which GenVec has been working to develop
                                                                  and manufacture adenovector-based HIV vaccines
                                                                  in collaboration with the VRC.
Last Updated                                                      8/25/2009
Partnering Details                                                2/9/2006 -- GenVec, Inc. announced that it has
                                                                  received initial funding of $300,000 to begin
                                                                  preliminary vector development with the Vaccine
                                                                  Research Center (VRC) of the National Institute of
                                                                  Allergy and Infectious Diseases (NIAID), National
                                                                  Institutes of Health, in preparation for the
                                                                  manufacture of clinical grade adenovector-based
                                                                  influenza vaccines.
5 . Respiratory Syncytial Virus Vaccine GENVEC
Disease Hub                                                       Respiratory and Pulmonary System
Therapeutic Indication                                            Respiratory Syncytial Virus (RSV) Infection
Current Trial                                                     PC
Description                                                       Respiratory Syncytial Virus Vaccine is based on
                                                                  adenovector technology. Adenovector delivers a
                                                                  gene that causes production of antigen, which then
                                                                  stimulates the desired immune reaction by the body.
                                                                  Respiratory Syncytial Virus Vaccine is being
                                                                  developed as a prophylactic and therapeutic vaccine
                                                                  against the infections due to respiratory syncytial
                                                                  virus (RSV).
Mechanism of Action                                               Not Applicable


GenVec Inc - Pipeline Report                                                                                         19

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Mode of Action                                                    Immunostimulant
Classification                                                    1) Biological> Immunologic and Biological Factors>
                                                                  > Biological Products> > > Vaccines> > > > Viral
                                                                  Vaccines

Trial Details                                                     Presently it is in preclinical trials
                                                                          Initial vaccine candidates are in preclinical
                                                                  testing. In May 2008, GenVec received a 2-year,
                                                                  USD 600,000 SBIR grant from the NIH to support
                                                                  work under this program.
                                                                          Source: SEC File: 10-K (3/16/2009)
Last Updated                                                      8/19/2009
Partnering Details                                                3/20/2007 -- GenVec announced that it has signed a
                                                                  Cooperative Research and Development Agreement
                                                                  with the National Institute of Allergy and Infectious
                                                                  Diseases, part of the National Institutes of Health, to
                                                                  develop adenovector-based vaccines for the
                                                                  prevention and treatment of respiratory syncytial
                                                                  virus. The collaborative research will combine
                                                                  NIAID's scientific and clinical expertise in RSV with
                                                                  GenVec's expertise in development of adenovector-
                                                                  based vaccines and proprietary manufacturing
                                                                  process. In addition to the RSV collaboration,
                                                                  GenVec is working with the NIAID on the clinical
                                                                  development of HIV and influenza vaccines.
6 . TherAtoh
Product Type                                                      Investigational drugs
Disease Hub                                                       Miscellaneous
Therapeutic Indication                                            Hearing Loss
Current Trial                                                     PC
Description                                                       TherAtoh is an adenovector for delivering the human
                                                                  atonal gene to trigger the production of therapeutic
                                                                  proteins by cells in the inner ear. Hearing and
                                                                  Balance require specialized cells of the inner ear
                                                                  called sensory hair cells, atonal (ATOH) induces the
                                                                  generation of these cells. TherAtoh is being
                                                                  developed for the treatment of hearing loss.
Mechanism of Action                                               Atonal Homolog 1 (ATOH1) Upregulator
Trial Details                                                     TherAtoh is in preclinical development for the
                                                                  treatment of Hearing Loss.
                                                                          Source: SEC File: 10-K (3/17/2008)
                                                                          February 6, 2007 GenVec, Inc. announced
                                                                  the publication of pre-clinical research
                                                                  demonstrating that delivery of the atonal gene
                                                                  (math1) can re-establish sensory cells and inner ear
                                                                  function. The proof of concept study in mouse


GenVec Inc - Pipeline Report                                                                                           20

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  vestibular models, Vestibular Hair Cell Regeneration
                                                                  and Restoration of Balance Function Induced by
                                                                  Math1 Gene Transfer, authored by investigators
                                                                  from University of Kansas School of Medicine,
                                                                  University of Heidelberg, and GenVec, appeared in
                                                                  the February issue of Otology & Neurotology
                                                                  (28:223-231), 2007. The researchers used GenVec's
                                                                  proprietary adenovector technology to deliver the
                                                                  company's patented math1 gene to inner ear cells in
                                                                  mice. In mice with damaged inner ear cells,
                                                                  treatment with AdMath1 regenerated inner ear hair
                                                                  cells and restored lost balance function within 8
                                                                  weeks.
                                                                          February 14, 2005 GenVec, Inc. reported
                                                                  that encouraging preclinical findings on a novel
                                                                  approach to treating hearing loss have been
                                                                  published in the March 2005 issue of Nature
                                                                  Medicine. The article, "Auditory Hair Cell
                                                                  Replacement and Hearing Improvement by Atoh1
                                                                  Gene Therapy in Deaf Mammals," describes
                                                                  research conducted by Yehoash Raphael, Ph.D. and
                                                                  colleagues at the University of Michigan, in which
                                                                  the delivery of GenVec's proprietary Atoh1 (MATH1)
                                                                  gene by the company's proprietary adenovector
                                                                  generated new hair cells in mature deaf guinea pig
                                                                  inner ears and improved hearing thresholds. The
                                                                  vibration of hair cells in the inner ear, when
                                                                  stimulated by sound, is crucial to normal hearing.
                                                                  The data suggest a possible new therapeutic
                                                                  approach to hearing loss may be found through
                                                                  delivery of certain developmental genes for hair cell
                                                                  regrowth in the inner ear.
                                                                          February 24, 2004 GenVec, Inc. announced
                                                                  research presentations for its hearing loss program
                                                                  at the 2004 Midwinter Meeting of the Association for
                                                                  Research in Otolaryngology (ARO) at the Adam's
                                                                  Mark Resort in Daytona Beach, Florida.
                                                                  Presentations demonstrate the feasibility of using
                                                                  GenVec's platform technology in the inner ear for
                                                                  hearing and balance disorders.
Last Updated                                                      8/18/2009
7 . Ad35HIV-EnvA Vaccine
Product Type                                                      Investigational drugs
Disease Hub                                                       Infections
Therapeutic Indication                                            AIDS/HIV (HIV-1 Infection)
Current Trial                                                     I


GenVec Inc - Pipeline Report                                                                                         21

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Description                                                       Ad35HIV-EnvA Vaccine is an adenovector based
                                                                  vaccine, which is based on adenovector technology.
                                                                  Adenovector delivers a gene that causes production
                                                                  of antigen, which then stimulates the desired
                                                                  immune reaction by the body. Ad35HIV-EnvA
                                                                  Vaccine is being developed as prophylactic vaccine
                                                                  for HIV-1 infection.
Mechanism of Action                                               Not Applicable
Mode of Action                                                    Immunostimulant;Prophylactic Vaccine
Classification                                                    1) Biological> Immunologic and Biological Factors>
                                                                  > Biological Products> > > Vaccines> > > > Viral
                                                                  Vaccines

Trial Details                                                     Presently it is in Phase I clinical trials
                                                                           June 21, 2007 GenVec, Inc. announced that
                                                                  the Vaccine Research Center (VRC) of the National
                                                                  Institute of Allergy and Infectious Diseases (NIAID),
                                                                  part of the National Institutes of Health (NIH), has
                                                                  begun a Phase I clinical trial to test a novel vaccine
                                                                  known as Ad35HIV-EnvA to prevent HIV-1 infection.
                                                                  This adenovector-based vaccine was developed
                                                                  under a collaborative research and development
                                                                  agreement (CRADA) between GenVec and the
                                                                  VRC. The two-part Phase I clinical study is designed
                                                                  to evaluate the safety, tolerability and
                                                                  immunogenicity of the Ad35-EnvA vaccine in
                                                                  comparison to and in combination with the Ad5-
                                                                  EnvA vaccine in prime-boost schedules. The first
                                                                  part of the study, a dose-escalation evaluation, will
                                                                  enroll 15 healthy adult volunteers. Three groups of
                                                                  five subjects each will receive one intramuscular
                                                                  injection of the vaccine at three different doses.
                                                                  Following vaccination of each dose group, an
                                                                  internal safety review will be conducted. The second
                                                                  phase of the study is designed to test prime-boost
                                                                  combinations of Ad5- and Ad35-based vaccines.
Last Updated                                                      8/18/2009
8 . AdPEDF
Product Type                                                      Investigational drugs
Disease Hub                                                       Ophthalmology and Optometry
Therapeutic Indication                                            Macular Degeneration (Wet Age-Related Macular
                                                                  Degeneration)
Current Trial                                                     I
Description                                                       AdPEDF uses adenovector to deliver the pigment
                                                                  epithelium derived factor (PEDF) gene that results in
                                                                  the local production of the PEDF protein, which is a


GenVec Inc - Pipeline Report                                                                                          22

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  key natural regulator of normal blood vessel growth
                                                                  in the eye and a neuro-protective agent of the
                                                                  photoreceptors. AdPEDF is being developed for the
                                                                  treatment of wet age-related macular degeneration.
Route of Administration                                           Intravitreal
Mechanism of Action                                               Serpin Peptidase Inhibitor, Clade F, Member 1
                                                                  (SERPINF1) Upregulator
Mode of Action                                                    Angiogenesis Inhibitor
Classification                                                    1) Biological> Amino Acids, Peptides, and Proteins>
                                                                  > Proteins> > > Intercellular Signaling Peptides and
                                                                  Proteins
                                                                  2) Biological> Amino Acids, Peptides, and Proteins>
                                                                  > Proteins> > > Nerve Tissue Proteins
                                                                  3) Biological> Amino Acids, Peptides, and Proteins>
                                                                  > Proteins> > > Eye Proteins
                                                                  4) Biological> Immunologic and Biological Factors>
                                                                  > Biological Factors
                                                                  5) Biological> Amino Acids, Peptides, and Proteins>
                                                                  > Proteins> > > Serpins

Trial Details                                                     Presently it is in Phase I clinical trials.
                                                                           Source: Company website
                                                                           GenVec, Inc. have completed a dose-
                                                                  escalation Phase I clinical trial of AdPEDF in
                                                                  patients with severe AMD. This Phase I study was
                                                                  expanded for testing of AdPEDF in AMD patients
                                                                  with less severe disease and, in March 2006,
                                                                  GenVec, Inc announced the completion of
                                                                  enrollment of this 22-patient trial. Data from this
                                                                  study are being collected for analysis.
                                                                           Source: SEC File: 10-K (2007).
                                                                           March 7, 2006 GenVec, Inc. announced the
                                                                  completion of enrollment in the company's follow-on
                                                                  Phase I study of its AdPEDF gene therapy in
                                                                  patients diagnosed recently with wet age-related
                                                                  macular degeneration (AMD). This 9-center clinical
                                                                  trial involves 20 patients who received a single
                                                                  injection of one of two doses of AdPEDF. Study
                                                                  participants will be evaluated at three and twelve
                                                                  weeks to assess changes in their vision and to
                                                                  confirm the drug's safety profile and will then be
                                                                  followed for one year after treatment. The trial
                                                                  includes several patients with refractory wet AMD
                                                                  who were treated previously with approved therapies
                                                                  but continued to lose vision, a problem in more than
                                                                  two-thirds of patients with AMD who receive


GenVec Inc - Pipeline Report                                                                                        23

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  treatment with anti-VEGF or photodynamic
                                                                  therapies.
                                                                           February 7, 2006 GenVec, Inc. announced
                                                                  the publication of results from a Phase I clinical
                                                                  study of its AdPEDF gene therapy in 28 patients with
                                                                  advanced neovascular age-related macular
                                                                  degeneration (AMD), a debilitating eye disorder. The
                                                                  findings, published in the February 2006 issue of
                                                                  Human Gene Therapy, showed evidence of a halt in
                                                                  disease progression lasting six to twelve months
                                                                  after patients received a single intravitreous injection
                                                                  of AdPEDF. There were no serious adverse events,
                                                                  severe ocular inflammation or dose-limiting toxicities
                                                                  reported.
                                                                           February 22, 2005 GenVec, Inc. announced
                                                                  that it has begun the second part of the Phase I
                                                                  clinical trial of its pigment epithelium-derived factor
                                                                  (AdPEDF) drug candidate for wet age-related
                                                                  macular degeneration (AMD).
                                                                           October 22, 2004 GenVec, Inc. announced
                                                                  the findings from a Phase I safety trial evaluating
                                                                  AdPEDF in patients with severe wet age- related
                                                                  macular degeneration (wet AMD). The Phase I,
                                                                  multi-center, open-label, dose-escalation study
                                                                  involved 28 patients with advanced disease at 8
                                                                  dose levels. Seven patients were included at the top
                                                                  dose level, 1 x 10(9.5) pu. No dose limiting toxicities,
                                                                  drug- related serious adverse events, or cases of
                                                                  infection in the eye (endophthalmitis) were seen.
                                                                  The few adverse events observed during the study
                                                                  were minor and not dose-related. Improvements in
                                                                  retinal appearance and stabilization of visual acuity
                                                                  in patients with very advanced disease were seen.
                                                                           April 28, 2004 GenVec, Inc. announced the
                                                                  results of the Phase I trial of AdPEDF in patients
                                                                  with severe wet age-related macular degeneration.
                                                                  The Phase I, multi-center, dose escalation study in
                                                                  patients with severe wet AMD demonstrated that
                                                                  AdPEDF was well tolerated at all dose levels,
                                                                  including patients treated at the highest dose. No
                                                                  dose limiting toxicities or drug related serious
                                                                  adverse events have been observed to date. In
                                                                  addition, no cases of significant ocular inflammation
                                                                  or endophthalmitis (infection) were reported. This
                                                                  interim data reports on 24 patients treated to date
                                                                  who received a single intravitreal injection of
                                                                  AdPEDF. Dose escalation in this study has

GenVec Inc - Pipeline Report                                                                                            24

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  increased by 3,000 fold from the initial dose.
                                                                  Investigators observed positive changes in visual
                                                                  acuity and retinal appearance at the higher dose
                                                                  levels.
                                                                            November 17, 2003 GenVec, Inc.
                                                                  announced the progress of the Phase I trial
                                                                  evaluating AdPEDF for safety in patients with wet
                                                                  age-related macular degeneration at a symposia of
                                                                  the American Academy of Ophthalmology Annual
                                                                  Meeting in Anaheim.
                                                                            May 05, 2003 GenVec, Inc. announced the
                                                                  dispaly of four posters on its ophthalmology product
                                                                  candidate, AdPEDF, during scientific presentations
                                                                  at the Association for Research in Vision and
                                                                  Ophthalmology (ARVO) Annual Meeting. Scientific
                                                                  presentations submitted by GenVec and their
                                                                  collaborators contain preclinical data on the
                                                                  Company's AdPEDF product candidate. In addition,
                                                                  two presentations focus on the attributes of
                                                                  GenVec's base technology and its application to
                                                                  ocular diseases. AdPEDF uses GenVec's
                                                                  proprietary adenovector technology to produce the
                                                                  pigment epithelium-derived factor (PEDF) protein, a
                                                                  natural inhibitor of angiogenesis, locally in the eye.
                                                                  Published preclinical studies using AdPEDF
                                                                  conducted at the Wilmer Eye Institute at Johns
                                                                  Hopkins University and GenVec demonstrate that
                                                                  AdPEDF not only prevents abnormal blood vessel
                                                                  growth, but also causes selective regression of
                                                                  existing diseased blood vasculature. PEDF is also a
                                                                  well-recognized neuroprotective agent.
                                                                            November 26, 2002 GenVec, Inc.
                                                                  announced the commencement of a Phase I clinical
                                                                  trial for its ophthalmology product candidate,
                                                                  AdPEDF, in patients with age-related macular
                                                                  degeneration (AMD). A total of up to 51 patients with
                                                                  severe AMD may be enrolled into this multi-center
                                                                  dose-escalating Phase I study with three to six
                                                                  patients per dose level and up to eight different dose
                                                                  levels. The primary endpoint in this Phase I study is
                                                                  safety.
Last Updated                                                      8/18/2009
9 . Malaria Vaccine GENVEC
Product Type                                                      Generic
Disease Hub                                                       Infections
Therapeutic Indication                                            Malaria


GenVec Inc - Pipeline Report                                                                                          25

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Current Trial                                                     II
Description                                                       Malaria Vaccine is a multi-antigen vaccine candidate
                                                                  that attacks both the blood and liver stages of
                                                                  malaria. It is based on two antigens, CSP and AMA,
                                                                  delivered utilizing adenovector technology. It is
                                                                  designed to generate a broad spectrum of immune
                                                                  responses including neutralizing antibodies and
                                                                  cytolytic T cell immunity. Malaria Vaccine is being
                                                                  developed as a therapeutic vaccine for malaria.
Mechanism of Action                                               Not Applicable
Mode of Action                                                    Immunostimulant;Therapeutic Vaccine
Classification                                                    1) Biological> Immunologic and Biological Factors>
                                                                  > Biological Products> > > Vaccines> > > >
                                                                  Protozoan Vaccines

Trial Details                                                     A Phase I/II clinical trial is being conducted by
                                                                  NMRC and funded by the United States Agency for
                                                                  International Development (USAID), the Military
                                                                  Infectious Diseases Research Program, and the
                                                                  Congressionally Directed Medical Research
                                                                  Program, which was initiated in January 2007.
                                                                           Source: SEC File: 10-K (3/16/2009)
                                                                           December 5, 2008 GenVec, Inc. announced
                                                                  that the company will present on GenVec's malaria
                                                                  vaccine program at the American Society of Tropical
                                                                  Medicine and Hygiene (ASTMH) 57th Annual
                                                                  Meeting, which will take place in New Orleans, LA
                                                                  on December 7- 11, 2008. Two presentations,
                                                                  highlighting research conducted in this program, will
                                                                  be given by GenVec scientists. Additional
                                                                  presentations, to be given by GenVec collaborators,
                                                                  will provide updates on malaria vaccine
                                                                  development, ranging from preclinical research
                                                                  through ongoing clinical studies using GenVec's
                                                                  core adenovector technology. Presentations are
                                                                  titled "Advanced generation adeno-based vectors for
                                                                  malaria vaccine development" and "Development of
                                                                  a multi-antigen multi-stage adenovector-based
                                                                  malaria vaccine that induces robust T-cell and
                                                                  antibody responses."
                                                                           June 12, 2008 GenVec, Inc.announced that
                                                                  encouraging clinical and preclinical data from
                                                                  GenVec's malaria vaccine program were presented
                                                                  at the Keystone Symposium-Malaria Immunology,
                                                                  Pathogenesis, and Vaccine Perspectives taking
                                                                  place June 8-13, 2008 in Alpbach, Austria. Data


GenVec Inc - Pipeline Report                                                                                         26

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  from the second cohort of volunteers in a Phase I/IIa
                                                                  clinical trial sponsored by the NMRC and the U.S.
                                                                  Military Malaria Vaccine Program showed a malaria
                                                                  vaccine candidate induced strong T-cell responses
                                                                  against the target antigens in all volunteers. The
                                                                  vaccine, developed under a cooperative research
                                                                  and development agreement (CRADA) between
                                                                  GenVec and NMRC and produced using GenVec's
                                                                  proprietary 293-ORF6 cell line and associated
                                                                  manufacturing process, is designed to provide
                                                                  protection against both liver and blood stages of the
                                                                  malaria parasite. NMRC scientists also presented
                                                                  preclinical data, collected under a separate GenVec
                                                                  collaboration with the PATH Malaria Vaccine
                                                                  Initiative and the NMRC, on a vaccine that delivers
                                                                  five malaria antigens and broadens the immune
                                                                  responses against both liver and blood stages of
                                                                  malaria.
                                                                           September 19, 2007 GenVec, Inc.
                                                                  announced that encouraging data from malaria
                                                                  vaccine studies using the company's adenovector
                                                                  technologies were reported in multiple presentations
                                                                  by scientists representing GenVec and its
                                                                  collaborators at the Malaria Vaccines for the World
                                                                  Conference at the Royal Society of Medicine in
                                                                  London, U.K., September 17-19, 2007. Data from
                                                                  the first cohort of volunteers in a Phase I/II clinical
                                                                  trial sponsored by the Naval Medical Research
                                                                  Center (NMRC) and the U.S. Military Malaria
                                                                  Vaccine Program showed this malaria vaccine
                                                                  candidate to be well tolerated and that it induced
                                                                  strong T-cell responses against the target antigens
                                                                  in all volunteers. The results were presented by
                                                                  scientists from NMRC. This vaccine, produced using
                                                                  GenVec's proprietary 293-ORF6 cell line and
                                                                  associated manufacturing process, is designed to
                                                                  provide protection against both the liver and blood
                                                                  stages of the parasite. NMRC is now enrolling
                                                                  volunteers to assess the safety and immunogenicity
                                                                  of a higher dose of the vaccine. After establishing
                                                                  that the vaccine is safe and well tolerated at the
                                                                  optimal dose, the next phase will evaluate the
                                                                  protective effects of the vaccine after malaria
                                                                  challenge. The ability to safely challenge human
                                                                  volunteers provides a unique opportunity to assess
                                                                  efficacy of candidate vaccines prior to field trials.
                                                                           January 17, 2007 GenVec, Inc. announced

GenVec Inc - Pipeline Report                                                                                           27

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  that they are collaborating with the Naval Medical
                                                                  Research Center (NMRC) in Silver Spring, MD, to
                                                                  conduct the first clinical study of an experimental
                                                                  malaria vaccine based on the company's gene
                                                                  delivery and cell culture manufacturing technologies
                                                                  for the production of recombinant adenovirus
                                                                  vaccine vectors. Under sponsorship from the United
                                                                  States Army Medical Materiel Development Activity
                                                                  (USAMMDA), and with financial support from the US
                                                                  Agency for International Development, the
                                                                  Congressionally Directed Peer Review Medical
                                                                  Program, and the Military Infectious Diseases
                                                                  Research Program, NMRC will initiate this FDA-
                                                                  approved study at their clinical trials center, located
                                                                  on the campus of the National Naval Medical Center
                                                                  in Bethesda. The first (safety) phase of the study will
                                                                  evaluate the safety and immunogenicity of two
                                                                  vaccine doses in healthy volunteers. After safety
                                                                  evaluation and confirmation of the optimal dose, the
                                                                  second (challenge) phase of the study will evaluate
                                                                  the protective effects of the vaccine following
                                                                  exposure to malaria. The ability to safely challenge
                                                                  human volunteers provides a unique opportunity for
                                                                  assessing the efficacy of candidate vaccines prior to
                                                                  the initiation of field trials.
                                                                           In collaboration with the Naval Medical
                                                                  Research Center (NMRC) and the Malaria Vaccine
                                                                  Initiative, GenVec is generating vaccine candidates
                                                                  for the prevention of malaria.
                                                                           Source: SEC file: 10-K (2006)
Last Updated                                                      8/18/2009
Partnering Details                                                9/10/2007 -- GenVec announced that it has entered
                                                                  into a collaborative research and development
                                                                  agreement with the U.S. Military Malaria Vaccine
                                                                  Program at the Walter Reed Army Institute of
                                                                  Research and the Naval Medical Research Center
                                                                  for the development and pre-clinical testing of a
                                                                  malaria vaccine candidate against Plasmodium
                                                                  vivax. More than 50 percent of malaria cases in US
                                                                  military personnel are caused by P. vivax, which is
                                                                  debilitating upon primary infection and can cause
                                                                  recurrent illness years after infection occurs. This
                                                                  malaria strain has a significant negative impact on
                                                                  world economic productivity and is a major threat to
                                                                  military preparedness.
                                                                           In addition to the CRADA, GenVec has
                                                                  signed a one-year contract with the Department of

GenVec Inc - Pipeline Report                                                                                           28

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  Defense to construct and test the adenovector-
                                                                  based vaccine, which carries a novel proprietary
                                                                  antigen against P. vivax developed by WRAIR
                                                                  scientists. GenVec and its collaborators will jointly
                                                                  design pre-clinical studies to evaluate the
                                                                  immunogenicity of the adenovector and WRAIR's
                                                                  recombinant sub-unit vaccine in various combination
                                                                  prime/boost vaccination strategies.
                                                                           3/31/2004 -- Update on July 27, 2009:
                                                                           GenVec, Inc. has expanded its existing
                                                                  contract with the PATH Malaria Vaccine Initiative
                                                                  (MVI), to support the development of vaccines to
                                                                  fight malaria through MVI and the United States
                                                                  Agency for International Development (USAID)
                                                                  funding. All the partners involved in this transaction
                                                                  are based in the US.
                                                                            GenVec is a biopharmaceutical company
                                                                  engaged in developing novel therapeutic drugs and
                                                                  vaccines, while MVI is a non-profit organization
                                                                  engaged in accelerating the development of malaria
                                                                  vaccines.
                                                                           The contract is valued at approximately $2
                                                                  million, would continue a collaboration that began in
                                                                  2004 and will initially support preclinical feasibility
                                                                  studies of novel adenovirus-based vaccines. Based
                                                                  on the results of the feasibility studies, GenVec,
                                                                  MVI, and USAID would contemplate preclinical and
                                                                  clinical development of these vaccines.
                                                                           Update on May 1, 2007:
                                                                           GenVec has amended and extended its
                                                                  existing collaborative research, development, and
                                                                  supply agreement (CRADS) with MVI. This
                                                                  amendment includes up to $0.75 million in additional
                                                                  funding through the end of 2007, to continue
                                                                  advancing a new multivalent malaria vaccine
                                                                  towards clinical evaluation.
                                                                           MVI has amended the original agreement to
                                                                  provide sufficient funding for GenVec and its
                                                                  collaborator, NMRC, to complete the last steps in
                                                                  pre-clinical development prior to the production of
                                                                  cGMP materials that will be required for human
                                                                  clinical evaluation.
                                                                            Announcement (March 31, 2004):
                                                                            GenVec, MVI and NMRC have entered into
                                                                  an agreement to enable scientists to assess whether
                                                                  five malaria antigens, (or) proteins, can generate
                                                                  strong immune responses alone or in combination.

GenVec Inc - Pipeline Report                                                                                           29

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                           Under a two year CRADS, MVI would
                                                                  provide GenVec up to $2.5 million for the production
                                                                  and evaluation of adenovirus vectors containing
                                                                  genes for up to five malaria antigens. GenVec'
                                                                  proprietary adenovector technology uses a
                                                                  replication deficient adenovector to deliver the genes
                                                                  to cause the production of beneficial antigens or
                                                                  proteins.
                                                                           Under a separate collaborative research and
                                                                  development agreement between GenVec and
                                                                  NMRC, NMRC scientists would provide GenVec with
                                                                  optimized malaria genes to be used in the
                                                                  adenovector vaccines. NMRC would then compare
                                                                  the effects of these vaccines alone and in
                                                                  combination in animal models.
                                                                           1/9/2003 -- GenVec announced that it has
                                                                  signed an initial contract with the U.S. Naval Medical
                                                                  Research Center allowing them to utilize GenVec's
                                                                  proprietary adenovector technology for the
                                                                  development of vaccines against malaria and the
                                                                  dengue virus. Under the two-year contract, GenVec
                                                                  will receive $1.9 million and will be responsible for
                                                                  constructing and producing adenovector-based
                                                                  vaccine candidates using its proprietary cell line and
                                                                  second-generation adenovector technology. The
                                                                  NMRC will test the vaccine candidates in preclinical
                                                                  models to assess safety and effectiveness. Clinical
                                                                  trials in humans would commence following
                                                                  successful preclinical testing results.
10 . rAd5 HIV- 1 Vaccine
Product Type                                                      Investigational drugs
Disease Hub                                                       Infections
Therapeutic Indication                                            AIDS/HIV (HIV Infection)
Current Trial                                                     II
Description                                                       rAd5 HIV- 1 Vaccine (HIV vaccine) is an
                                                                  adenovector-based vaccine candidate targeted
                                                                  against the major strains of HIV and is designed to
                                                                  attack the virus on both antibody (B-cell) and cellular
                                                                  (T-cell) levels. Ad35HIV-EnvA Vaccine is based on
                                                                  adenovector technology. Adenovector delivers a
                                                                  gene that causes production of antigen, which then
                                                                  stimulates the desired immune reaction by the body.
                                                                  rAd5 HIV- 1 Vaccine is being developed as
                                                                  prophylactic vaccine for HIV infection.
Mechanism of Action                                               Not Applicable
Mode of Action                                                    Immunostimulant;Prophylactic Vaccine


GenVec Inc - Pipeline Report                                                                                           30

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Classification                                                    1) Biological> Immunologic and Biological Factors>
                                                                  > Biological Products> > > Vaccines> > > > Viral
                                                                  Vaccines

Trial Details                                                     Presently it is in Phase II clinical trials
                                                                           August 23, 2007 GenVec, Inc. announced
                                                                  that results from multiple ongoing clinical trials
                                                                  utilizing its adenovector vaccine technologies were
                                                                  presented at the AIDS Vaccine 2007 Conference.
                                                                  The trials, which are investigating a DNA prime-
                                                                  adenoviral vector boost strategy, incorporate a
                                                                  multiclade rAd5 HIV- 1 vaccine developed by
                                                                  GenVec in collaboration with the Vaccine Research
                                                                  Center ("VRC"), National Institute of Allergy and
                                                                  Infectious Diseases, National Institutes of Health
                                                                  ("NIH"). In the TRIAD Phase II trial, immunogenicity
                                                                  was achieved in approximately seventy percent of
                                                                  the vaccinated population. Importantly, the effect of
                                                                  pre-existing Ad5 immunity on immunogenicity of the
                                                                  vaccine appeared to be small.
                                                                           The Vaccine Research Center (VRC) has
                                                                  completed multiple Phase I clinical trials and is
                                                                  currently conducting multiple Phase IIa clinical trials,
                                                                  including an international 480-subject study. In
                                                                  addition, this vaccine candidate is being tested as a
                                                                  therapeutic vaccine in a 15 subject, Phase I study
                                                                  with the objective to determine safety and collect
                                                                  evidence of efficacy as measured by
                                                                  immunogenicity and reduction in viral load. GenVec
                                                                  has manufactured late-stage clinical supplies for a
                                                                  proof-of-concept efficacy trial where approximately
                                                                  8,000 individuals will be enrolled in a Phase IIb
                                                                  international study.
                                                                           Source: SEC file: 10-K (3/16/2007)
                                                                           December 15, 2006 GenVec, Inc.
                                                                  announced the publication of an article and
                                                                  accompanying editorial reporting positive results of
                                                                  Phase I human trials using this HIV vaccine, in trials
                                                                  being conducted by the National Institutes of Health
                                                                  (NIH) Vaccine Research Center (VRC). It is the first
                                                                  published clinical research on an adenovirus-based
                                                                  HIV vaccine candidate. In the Phase I dose
                                                                  escalation trial the vaccine was tested in healthy,
                                                                  uninfected adult volunteers, and was found safe and
                                                                  well tolerated at multiple doses. This vaccine is
                                                                  based on GenVec's proprietary adenovirus vector
                                                                  technology. A single injection induced HIV-1 antigen

GenVec Inc - Pipeline Report                                                                                            31

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  specific T cell responses in 28 (93%) and 18 (60%)
                                                                  of 30 vaccine recipients for CD4 and CD8 T cells,
                                                                  respectively. Env-specific antibody responses were
                                                                  detected in 28 (93%) of 30 vaccine recipients.
                                                                           August 31, 2006 GenVec, Inc. announced
                                                                  that results from multiple Phase I clinical trials were
                                                                  presented at theAIDS Vaccine 2006 Conference in
                                                                  Amsterdam. The HIV vaccine incorporating
                                                                  GenVec's adenovector-based technology was well
                                                                  tolerated, and results were consistent with
                                                                  previously reported data: induction of potent immune
                                                                  responses when the vaccine was used alone or in
                                                                  combination with a DNA primer vaccine. The results
                                                                  support the rationale for advanced clinical testing. In
                                                                  a study of the HIV vaccine incorporating GenVec's
                                                                  adenovector-based technology given to 40
                                                                  volunteers as a single dose of either 1e10 Particle
                                                                  Units (PU) or 1e11 PU,both doses showed
                                                                  stimulation of T-cells against the multiple antigens
                                                                  contained in this vaccine. The study was presented
                                                                  by Dr. Larry Peiperl of University of California School
                                                                  of Medicine San Francisco, and the study was
                                                                  conducted by the HIV Vaccine TrialsNetwork
                                                                  (HVTN).
                                                                           September 7, 2005 GenVec, Inc. announced
                                                                  that preliminary safety and immune response data in
                                                                  a limited sample size of eight healthy volunteers
                                                                  enrolled in one of several ongoing Phase I clinical
                                                                  trials involving an HIV vaccine candidate developed
                                                                  by GenVec and the Vaccine Research Center (VRC)
                                                                  of the National Institute of Allergy and Infectious
                                                                  Diseases, National Institutes of Health (NIH),
                                                                  showed that the vaccine regimen combining DNA
                                                                  priming and adenovector boosting was well tolerated
                                                                  and produced a vigorous cellular and antibody
                                                                  immune response. These preliminary findings were
                                                                  presented at the AIDS Vaccine 2005 International
                                                                  Conference in Montreal, Canada by Barney S.
                                                                  Graham, M.D., Ph.D., the VRC study investigator. In
                                                                  this study, the anti-HIV response was elicited in
                                                                  eight healthy volunteers who received a DNA prime
                                                                  vaccine followed by an adenovector-based booster
                                                                  vaccine shot. In subjects who had received prior
                                                                  DNA priming, cellular and antibody responses were
                                                                  several fold higher following the adenovector
                                                                  vaccine booster than in subjects who had received
                                                                  either DNA alone or the adenovector vaccine alone.

GenVec Inc - Pipeline Report                                                                                           32

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  The booster was administered up to 26 months after
                                                                  the DNA prime vaccine.
                                                                           April 15, 2005 GenVec, Inc. announced that
                                                                  safety and immune response data were presented
                                                                  from the first of several ongoing Phase I clinical trials
                                                                  involving an HIV vaccine candidate developed jointly
                                                                  by GenVec and the Vaccine Research Center (VRC)
                                                                  of the National Institute of Allergy and Infectious
                                                                  Diseases, part of the National Institutes of Health.
                                                                  The data presented showed that the vaccine was
                                                                  well-tolerated and immunogenic at each dose level.
                                                                           January 19, 2005 GenVec, Inc. announced
                                                                  that the National Institute of Allergy and Infectious
                                                                  Diseases, National Institutes of Health, has begun
                                                                  the second Phase I clinical trial in healthy adult
                                                                  volunteers of an HIV vaccine candidate jointly
                                                                  developed by the Dale and Betty Bumpers Vaccine
                                                                  Research Center (VRC), a part of NIAID, and
                                                                  GenVec. This second Phase trial will preliminarily
                                                                  assess whether administration of the adenovector-
                                                                  based vaccine is safe and well-tolerated in
                                                                  volunteers previously immunized with an HIV DNA
                                                                  vaccine candidate invented by the VRC.
                                                                  Approximately 60 healthy, HIV-negative volunteers
                                                                  will receive an adenovector- based HIV booster shot
                                                                  between six and nine months after receiving the
                                                                  initial HIV DNA vaccination; 10 additional HIV-
                                                                  negative volunteers will receive placebo.
                                                                           July 28, 2004 GenVec, Inc. announced that
                                                                  the Vaccine Research Center (VRC) of the National
                                                                  Institute of Allergy and Infectious Diseases (NIAID)
                                                                  of the National Institutes of Health (NIH) has initiated
                                                                  a Phase I clinical study to test an HIV vaccine
                                                                  candidate developed utilizing GenVec's proprietary
                                                                  gene delivery technology. The study will be
                                                                  sponsored, managed and funded by NIAID and will
                                                                  employ HIV vaccine candidates produced by
                                                                  GenVec under its subcontract with SAIC-Frederick,
                                                                  Inc. (SAIC) and developed in collaboration with
                                                                  NIAID under a Cooperative Research and
                                                                  Development Agreement (CRADA). This Phase I,
                                                                  dose escalating, double blind, placebo controlled
                                                                  study is designed to assess safety and immune
                                                                  response.
                                                                           February 05, 2002 GenVec, Inc. announced
                                                                  that it has signed a contract with the Vaccine
                                                                  Research Center at the National Institute of Allergy

GenVec Inc - Pipeline Report                                                                                             33

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                 and Infectious Diseases (NIAID) of the National
                                                 Institutes of Health (NIH) under which GenVec will
                                                 use its proprietary adenovector technology for the
                                                 development and manufacture of clinical grade
                                                 preventative AIDS vaccine candidates. Under the
                                                 contract, GenVec is tasked with developing and
                                                 manufacturing adenovector-based preventative
                                                 AIDS vaccine candidates using its proprietary cell
                                                 line and adenovector technology.
Last Updated                                     8/19/2009
11 . rAd5 HIV- 1 Vaccine with Plasmid DNA Vaccine Prime
Disease Hub                                      Infections
Therapeutic Indication                           AIDS/HIV
Current Trial                                    II
Description                                      rAd5 HIV- 1 Vaccine (HIV vaccine) is an
                                                 adenovector-based vaccine candidate targeted
                                                 against the major strains of HIV and is designed to
                                                 attack the virus on both antibody (B-cell) and cellular
                                                 (T-cell) levels. Ad5HIV-EnvA Vaccine is based on
                                                 adenovector technology. Adenovector delivers a
                                                 gene that causes production of antigen, which then
                                                 stimulates the desired immune reaction by the body.
                                                 rAd5 HIV- 1 Vaccine with plasmid DNA vaccine
                                                 prime is being developed as prophylactic vaccine for
                                                 HIV infection.
Mechanism of Action                              Not Applicable
Mode of Action                                   Immunostimulant
Trial Details                                    Presently it is in Phase II clinical trials
                                                          The vaccine candidate (VRC-HIVADV014-
                                                 00VP) is being evaluated alone and in combination
                                                 with a plasmid DNA vaccine prime. In October
                                                 2005, the VRC announced the initiation of Phase II
                                                 testing for this vaccine candidate.
                                                          Source: Company website
                                                          October 11, 2005 GenVec, Inc. announced
                                                 that the Vaccine Research Center (VRC) of the
                                                 National Institute of Allergy and Infectious Diseases
                                                 (NIAID), National Institutes of Health, has begun
                                                 Phase II clinical testing of an experimental
                                                 adenovector-based HIV vaccine candidate
                                                 developed in collaboration between GenVec and the
                                                 VRC. The double-blind, placebo-controlled Phase II
                                                 study will enroll a total of 480 healthy volunteers who
                                                 will be randomized 1:1 to receive either vaccine or
                                                 placebo. The treatment group will receive a DNA
                                                 plasmid injection (the "prime") followed by the


GenVec Inc - Pipeline Report                                                                          34

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                         adenovector-based booster vaccine. Both vaccines
                                                                         contain DNA segments from the three major HIV
                                                                         subtypes, or "clades," responsible for approximately
                                                                         85 percent of HIV infections worldwide. The placebo
                                                                         group will receive saline injections.
                                                                                  In September 2005, National Institute of
                                                                         Allergy and Infectious Diseases initiated a Phase II
                                                                         clinical trial to evaluate the safety and
                                                                         immunogenicity of a multiclade HIV-1 DNA plasmid
                                                                         vaccine, VRC-HIVDNA016-00-VP, followed by a
                                                                         multiclade recombinant adenoviral vector HIV-1
                                                                         vaccine boost, VRC-HIVADV014-00-VP, in HIV-1
                                                                         Uninfected Adult Participants. The purpose of the
                                                                         study is to determine the safety of and immune
                                                                         response to a DNA HIV vaccine followed by an
                                                                         adenoviral vector HIV vaccine in HIV uninfected
                                                                         adults.
                                                                                  Source: Clinicaltrials.gov
Last Updated                                                             9/9/2009
12 . TNFerade with Capecitabine and Radiotherapy
Product Type                                                             Investigational drugs
Disease Hub                                                              Cancer
Therapeutic Indication                                                   Colorectal Cancer (Locally Advanced Rectal Cancer)
Current Trial                                                            II
Description                                                              TNFerade is an adenovector, or DNA carrier, which
                                                                         contains the gene for tumor necrosis factor-alpha,
                                                                         golnerminogene pradenovec, with potent and well-
                                                                         documented anti-cancer effects, for direct injection
                                                                         into tumors. TNFerade, which is based on
                                                                         adenovector technology, stimulates the production
                                                                         of TNF-alpha in the tumor after the direct injection
                                                                         into the tumors. It enables the controlled production
                                                                         over a specific period of time of the TNF-alpha
                                                                         protein inside the tumor while avoiding unwanted
                                                                         exposure to healthy tissue. Capecitabine (oral) is an
                                                                         antimetabolite that inhibits DNA synthesis and slows
                                                                         growth of tumor tissue. TNFerade with Capecitabine
                                                                         and Radiotherapy is being developed for the
                                                                         treatment of biopsy-proven locally advanced rectal
                                                                         cancer.
Mechanism of Action                                                      Thymidylate Synthase (TS) Inhibitor;Tumor Necrosis
                                                                         Factor (TNF) Upregulator
Mode of Action                                                           Anticancer;DNA Repair Disrupter
                                                                  capecitabine
Chemical Name                                                            pentyl N-[1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-methyl-
                                                                         oxolan-2-yl]-5-fluoro-2-oxo-pyrimidin-4-yl]carbamate


GenVec Inc - Pipeline Report                                                                                                35

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Chemical Structure




Molecular Weight                                                 359.352
Molecular Formula                                                C15-H22-F-N3-O6
Molecule Type                                                    Small
Classification                                                   1) Chemical> Nucleic Acids, Nucleotides, and
                                                                 Nucleosides> > Nucleosides> > >
                                                                 Deoxyribonucleosides> > > > Deoxycytidine
                                                                 2) Chemical> Nucleic Acids, Nucleotides, and
                                                                 Nucleosides> > Nucleosides> > > Pyrimidine
                                                                 Nucleosides> > > > Cytidine
                                                                 3) Chemical> Heterocyclic Compounds> >
                                                                 Heterocyclic Compounds, 1-Ring> > > Pyrimidines
                                                    golnerminogene pradenovec
Chemical Name                                                    DNA (synthetic human adenovirus 5 adenoviral
                                                                 vector AdGVEGR.TNF.11D)

Trial Details                                                     Presently it is in Phase II clinical trials
                                                                          A Phase II trial occurred to assess the ability
                                                                  of TNFerade to improve tumor responses in
                                                                  conjunction with standard chemoradiation. This
                                                                  single-site study was done in collaboration with the
                                                                  National Cancer Institute of the NIH and was
                                                                  designed to compare TNFerade plus standard of
                                                                  care therapy with standard of care therapy in the
                                                                  treatment of patients with biopsy-proven rectal
                                                                  cancer.
                                                                          Source: Source: SEC File: 10-K (12/31/2008)
                                                                          TNFerade is being studied in Phase II trials
                                                                  for rectal cancer, A Phase II trial is in progress to
                                                                  assess the ability of TNFerade to improve tumor
                                                                  responses in conjunction with standard
                                                                  chemoradiation. This single-site study is being done
                                                                  in collaboration with the National Cancer Institute
                                                                  and is designed to compare TNFerade plus standard
                                                                  of care therapy versus standard of care therapy in
                                                                  the treatment of patients with biopsy-proven rectal
                                                                  cancer.
                                                                          Source: SEC File: 10-K (3/17/2008)
                                                                          October 31, 2007 GenVec, Inc. announced
                                                                  encouraging early results of a Phase II study with
                                                                  TNFerade in patients with locally advanced rectal


GenVec Inc - Pipeline Report                                                                                           36

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  cancer. The findings were presented in a poster
                                                                  session at the 49th Annual Meeting of the American
                                                                  Society for Therapeutic Radiology and Oncology in
                                                                  Los Angeles by Dr. Bronwyn Stall, Radiation
                                                                  Oncology Branch, National Cancer Institute, which is
                                                                  conducting the trial. The study is assessing the
                                                                  feasibility of adding TNFerade to pre-operative
                                                                  chemoradiation, the current standard of care for
                                                                  locally advanced rectal cancer, to decrease local
                                                                  recurrence, improve pathological response, and
                                                                  increase the probability of sphincter preservation as
                                                                  a surgical outcome. The Phase II study enrolled
                                                                  seven patients with locally advanced rectal cancer.
                                                                  TNFerade was administered weekly to patients via
                                                                  intratumoral injections during the first five weeks of
                                                                  radiotherapy. All patients also received oral
                                                                  capecitabine twice daily during radiotherapy.
                                                                  Surgical removal of the tumor was done 6-9 weeks
                                                                  following therapy. The treatment was both feasible
                                                                  and appeared to be well tolerated. Prior to
                                                                  treatment, four of the seven patients were classified
                                                                  as highly likely to need sphincter removing surgery
                                                                  with colostomy. Subsequent to TNFerade plus
                                                                  chemoradiation, all seven patients who underwent
                                                                  surgical resection had successful sphincter sparing
                                                                  procedures. Five of the seven patients achieved
                                                                  pathological complete response. Based on these
                                                                  preliminary data, the NCI study is continuing to
                                                                  enroll more patients.
                                                                            May 25, 2005 GenVec, Inc. announced that
                                                                  the U.S. Food and Drug Administration informed the
                                                                  company that it may resume its Phase II clinical trial
                                                                  of TNFerade in rectal cancer. This trial will be
                                                                  conducted in collaboration with the Surgery Branch
                                                                  of the National Cancer Institute to evaluate the use
                                                                  of TNFerade in combination with chemoradiation for
                                                                  rectal cancer to improve complete response rates,
                                                                  surgical outcomes and survival. The FDA indicated
                                                                  that the clinical hold issues have been satisfactorily
                                                                  addressed for the rectal and esophageal indications
                                                                  and, as such, the clinical hold has been removed
                                                                  from the TNFerade IND.
                                                                            In October 2004, the FDA placed the
                                                                  TNFerade clinical program on hold due to blood
                                                                  clots seen in patients with esophageal cancer in the
                                                                  dose escalating portion of the esophageal Phase II
                                                                  trial. In response, GenVec submitted data to the

GenVec Inc - Pipeline Report                                                                                          37

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                  FDA and requested permission to move forward only
                                                  with the pancreatic study.
                                                           Source:10-K (2005)
                                                           In connection with a Cooperative Research
                                                  and Development Agreement entered into between
                                                  the Company and the National Cancer Institute
                                                  (NCI) in October 2003, the NCI has opened a single-
                                                  site Phase II trial testing TNFerade in patients with
                                                  rectal cancer.
                                                           Source: SEC file: 10-K (2004)
                                                           October 23, 2003 GenVec, Inc. announced
                                                  that it has entered into a formal collaboration with
                                                  the National Cancer Institute (NCI) by signing a
                                                  Cooperative Research and Development Agreement
                                                  (CRADA). Dr. Steven K. Libutti of the NCI Surgery
                                                  Branch will conduct a Phase II clinical study to
                                                  determine the activity of TNFerade, GenVec's lead
                                                  oncology product candidate, in rectal cancer.
Last Updated                                      8/28/2009
Partnering Details                                10/23/2003 -- GenVec, Inc. announced that it has
                                                  entered into a formal collaboration with the National
                                                  Cancer Institute (NCI) by signing a Cooperative
                                                  Research and Development Agreement (CRADA).
                                                  Under the terms of this agreement, GenVec will
                                                  provide the NCI with clinical supplies of its
                                                  proprietary TNFerade product candidate for the
                                                  study.
                                                           In addition to this trial, the NCI will work with
                                                  GenVec to test mutually agreed upon second-
                                                  generation TNF (tumor necrosis factor) product
                                                  candidates that target tumors when given
                                                  systemically or regionally.
13 . TNFerade with Cetuximab, Radiotherapy (First Line)
Disease Hub                                       Cancer
Therapeutic Indication                            Head and Neck Cancer (Head and Neck Cancer in
                                                  Elderly or Frail Patients)
Current Trial                                     II
Description                                       TNFerade is an adenovector, or DNA carrier, which
                                                  contains the gene for tumor necrosis factor-alpha,
                                                  golnerminogene pradenovec, with potent and well-
                                                  documented anti-cancer effects, for direct injection
                                                  into tumors. TNFerade, which is based on
                                                  adenovector technology, stimulates the production
                                                  of TNF-alpha in the tumor after the direct injection
                                                  into the tumors. It enables the controlled production
                                                  over a specific period of time of the TNF-alpha


GenVec Inc - Pipeline Report                                                                              38

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                protein inside the tumor while avoiding unwanted
                                                exposure to healthy tissue. Cetuximab is a highly
                                                specific chimerized monoclonal antibody that binds
                                                to EGFR and blocks the ability of EGF to initiate
                                                receptor activation and signaling to the tumor.
                                                Irinotecan acts by binding to the topoisomerase I-
                                                DNA complex and prevents religation of the single-
                                                strand breaks. TNFerade with Cetuximab,
                                                Radiotherapy is being developed as first line therapy
                                                for the treatment of locally advanced head and neck
                                                cancer in elderly or frail patients.
Route of Administration                         Intratumor
Mechanism of Action                             Epidermal Growth Factor Receptor (EGFR)
                                                Antagonist;Tumor Necrosis Factor (TNF)
                                                Upregulator
Mode of Action                                  Angiogenesis Inhibitor;Anticancer;Apoptosis Inducer
Trial Details                                   GenVec Inc initiated a Phase I/II treatment, non-
                                                randomized, open label, uncontrolled, single group
                                                assignment, safety/efficacy study of radiotherapy,
                                                cetuximab, and intratumoral injections of TNFerade
                                                biologic for elderly or frail patients or intermediate
                                                stage patients with head and neck cancer. This
                                                study is looking at the safety and tolerability of
                                                TNFerade biologic combined with conventional once
                                                daily radiation therapy in elderly or frail patients with
                                                new onset locally advanced head and neck tumors.
                                                This study is recruiting participants.
                                                         Source: Clinicaltrials.gov
Last Updated                                    8/28/2009
14 . TNFerade with Concomitant Radiotherapy and Chemotherapy (Second Line)
Product Type                                    Investigational drugs
Disease Hub                                     Cancer
Therapeutic Indication                          Head and Neck Cancer (Unresectable, Recurrent
                                                Head and Neck Cancer (Second Line Therapy))
Current Trial                                   II
Description                                     TNFerade is an adenovector, or DNA carrier, which
                                                contains the gene for tumor necrosis factor-alpha,
                                                golnerminogene pradenovec, with potent and well-
                                                documented anti-cancer effects, for direct injection
                                                into tumors. TNFerade, which is based on
                                                adenovector technology, stimulates the production
                                                of TNF-alpha in the tumor after the direct injection
                                                into the tumors. It enables the controlled production
                                                over a specific period of time of the TNF-alpha
                                                protein inside the tumor while avoiding unwanted
                                                exposure to healthy tissue. Fluorouracil is a


GenVec Inc - Pipeline Report                                                                           39

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                        fluorinated pyrimidine that acts as an antimetabolite
                                                                        antineoplastic agent. It acts by halting DNA
                                                                        synthesis and replication by inhibiting the enzyme
                                                                        thymidylate synthetase. Hydroxyurea (TNF-FHX) is
                                                                        a cell cycle-phase specific antineoplastic agent. It
                                                                        blocks ribonucleotide reductase, the rate-limiting
                                                                        enzyme of DNA synthesis which is responsible for
                                                                        converting ribonucleotides to deoxyribonucleotide
                                                                        triphosphates (dNTPs) that are critical to DNA
                                                                        synthesis and repair. TNFerade with Concomitant
                                                                        Radiotherapy and Chemotherapy is being developed
                                                                        as the second-line treatment of head and neck
                                                                        cancer.
Mechanism of Action                                                     Thymidylate Synthase (TS) Inhibitor;Tumor Necrosis
                                                                        Factor (TNF) Upregulator
Mode of Action                                                          Anticancer;DNA Repair Disrupter
                                                                  Fluorouracil
Chemical Name                                                           5-fluoro-1H-pyrimidine-2,4-dione
Chemical Structure




Molecular Weight                                                 130.078
Molecular Formula                                                C4-H3-F-N2-O2
Molecule Type                                                    Small
Classification                                                   1) Chemical> Heterocyclic Compounds> >
                                                                 Heterocyclic Compounds, 1-Ring> > > Pyrimidines
                                                    golnerminogene pradenovec
Chemical Name                                                    DNA (synthetic human adenovirus 5 adenoviral
                                                                 vector AdGVEGR.TNF.11D)
                                                           hydroxyurea
Chemical Name                                                    hydroxyurea
Chemical Structure


Molecular Weight                                                         76.0546
Molecular Formula                                                        C-H4-N2-O2
Molecule Type                                                            Small
Classification                                                           1) Chemical> Organic Chemicals> > Urea

Trial Details                                                            A Phase I/II safety, tolerability and "Proof of
                                                                         Concept" study of TNFerade Biological in
                                                                         combination with concomitant radiotherapy,
                                                                         fluorouracil, and hydroxyurea (TNF-FHX) for patients
                                                                         with unresectable recurrent head and neck Cancer

GenVec Inc - Pipeline Report                                                                                               40

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  (the "TNF-CORE" Trial) is ongoing at the University
                                                                  of Chicago Medical Center. In the "CORE" trial,
                                                                  TNFeradeT is administered at three different dose
                                                                  levels in conjunction with radiation + Fluorouracil +
                                                                  Hydroxyurea treatment in the Phase I (dose-finding
                                                                  portion), and then the established dosage will be
                                                                  tested for its ability to improve clinical outcome for
                                                                  patients. The primary endpoint for this trial is
                                                                  locoregional control at 24 months. Locoregional
                                                                  control at 3, 6 and 12 months, as well as tumor
                                                                  response rate, progression-free survival at 3, 6, 12
                                                                  and 24 months, and the rate of metastases at 3, 6,
                                                                  12 and 24 months will also be assessed.
                                                                           Source: Company website
                                                                           GenVec is sponsoring two separate Phase
                                                                  I/II studies at the University of Chicago to explore
                                                                  the use of TNFerade as a component of standard of
                                                                  care treatment for head and neck cancer, a disease
                                                                  where local control is crucial for effective treatment
                                                                  and considered an accepted regulatory endpoint for
                                                                  this indication. The two studies were initiated in
                                                                  January 2007 and are being funded, in part, by the
                                                                  National Cancer Institute. The first study will enroll
                                                                  up to 70 patients and examine TNFerade as a
                                                                  second-line treatment for inoperable, recurrent
                                                                  tumors. The second study will enroll up to 60 elderly
                                                                  or frail patients with new onset, locally advanced
                                                                  disease. Investigators will first determine the best
                                                                  dose in each indication, and will assess safety and
                                                                  the ability of TNFerade to control the local spread of
                                                                  the cancer following treatment.
                                                                           Source: SEC File: 10-K (3/17/2008)
                                                                           May 31, 2008 GenVec, Inc presented, in a
                                                                  poster session, encouraging data from Phase I
                                                                  clinical trial of TNFerade in patients with head and
                                                                  neck cancer, at the annual meeting of the American
                                                                  Society for Clinical Oncology (ASCO) in Chicago, IL.
                                                                           January 26, 2007 GenVec, Inc announced
                                                                  that the first patient has been dosed in a Phase I/II
                                                                  trial with TNFerade for head and neck cancer at the
                                                                  University of Chicago Medical Center. GenVec is
                                                                  sponsoring two separate Phase I/II studies at the
                                                                  University of Chicago to explore the use of
                                                                  TNFerade as a second-line treatment for
                                                                  unresectable, recurrent tumors, and as a first-line
                                                                  treatment for elderly or frail patients. The trials are
                                                                  being funded by the National Cancer Institute. The

GenVec Inc - Pipeline Report                                                                                           41

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                               two separate trials, which will be led by principal
                                               investigators Everett Vokes, M.D., and Tanguy
                                               Seiwert, M.D., could enroll up to 70 patients with
                                               unresectable, recurrent tumors and up to 60 elderly
                                               or frail patients with new onset, locally advanced
                                               disease. The investigators will first determine best
                                               dose in each indication, and will assess safety and
                                               locoregional control of the cancer following
                                               TNFerade treatment as a component of standard of
                                               care.
Last Updated                                   8/28/2009
15 . TNFerade with Radiotherapy and Chemotherapy (First Line)
Product Type                                   Investigational drugs
Disease Hub                                    Cancer
Therapeutic Indication                         Esophageal Cancer (Locally Advanced Resectable
                                               Esophageal Cancer)
Current Trial                                  II
Description                                    TNFerade is an adenovector, or DNA carrier, which
                                               contains the gene for tumor necrosis factor-alpha,
                                               golnerminogene pradenovec, with potent and well-
                                               documented anti-cancer effects, for direct injection
                                               into tumors. TNFerade, which is based on
                                               adenovector technology, stimulates the production
                                               of TNF-alpha in the tumor after the direct injection
                                               into the tumors. It enables the controlled production
                                               over a specific period of time of the TNF-alpha
                                               protein inside the tumor while avoiding unwanted
                                               exposure to healthy tissue. Fluorouracil is a
                                               fluorinated pyrimidine that acts as an antimetabolite
                                               antineoplastic agent. It acts by halting DNA
                                               synthesis and replication by inhibiting the enzyme
                                               thymidylate synthetase. Cisplatin is a bifunctional
                                               cytotoxic alkylating agent. It reacts with DNA to
                                               produce both intra and interstrand crosslink and
                                               impairs replication and transcription of DNA and
                                               causes cellular arrest in the G2 phase of the cell
                                               cycle. TNFerade with Radiotherapy and
                                               Chemotherapy is being developed as a first-line
                                               treatment of locally advanced resectable esophageal
                                               cancer.
Mechanism of Action                            DNA Complexation;Thymidylate Synthase (TS)
                                               Inhibitor;Tumor Necrosis Factor (TNF) Upregulator
Mode of Action                                 Anticancer;Apoptosis Inducer;Cell Cycle
                                               Inhibitor;Cytotoxic Agent;DNA Repair Disrupter;DNA
                                               Synthesis Inhibitor;G2 Phase Inhibitor
                                          Cisplatin


GenVec Inc - Pipeline Report                                                                      42

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Chemical Name                                                           azane; platinum(+2) cation; dichloride
Chemical Structure


Molecular Weight                                                        300.045
Molecular Formula                                                       C12-H6-N2-Pt
Molecule Type                                                           Small
Classification                                                          1) Chemical> Inorganic Chemicals> > Chlorine
                                                                        Compounds
                                                                        2) Chemical> Inorganic Chemicals> > Nitrogen
                                                                        Compounds
                                                                        3) Chemical> Inorganic Chemicals> > Platinum
                                                                        Compounds
                                                                  Fluorouracil
Chemical Name                                                           5-fluoro-1H-pyrimidine-2,4-dione
Chemical Structure




Molecular Weight                                                 130.078
Molecular Formula                                                C4-H3-F-N2-O2
Molecule Type                                                    Small
Classification                                                   1) Chemical> Heterocyclic Compounds> >
                                                                 Heterocyclic Compounds, 1-Ring> > > Pyrimidines
                                                    golnerminogene pradenovec
Chemical Name                                                    DNA (synthetic human adenovirus 5 adenoviral
                                                                 vector AdGVEGR.TNF.11D)

Trial Details                                                           Presently it is in Phase II clinical trials
                                                                                 May 29, 2008 GenVec, Inc. presented an
                                                                        overview of TNFerade development and an update
                                                                        on long-term survival data from its Phase II clinical
                                                                        trial using TNFerade in patients with esophageal
                                                                        cancer at the American Society of Gene Therapy
                                                                        (ASGT) 11th Annual Meeting in Boston, MA.
                                                                                 May 23, 2006 GenVec, Inc. announced that
                                                                        Kenneth Chang, M.D., medical director of the
                                                                        Comprehensive Digestive Disease Center at the
                                                                        University of California at Irvine and a clinical
                                                                        investigator for several studies involving GenVec's
                                                                        investigational cancer drug TNFerade presented
                                                                        updated survival information from a clinical study
                                                                        demonstrating the potential utility of TNFerade in
                                                                        treating patients with esophageal cancer. The study
                                                                        compared the safety and efficacy of four different


GenVec Inc - Pipeline Report                                                                                                43

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  doses of TNFerade in 24 patients with locally
                                                                  advanced resectable esophageal cancer prior to
                                                                  surgery. Overall patient survival for all dose levels is
                                                                  currently 83 percent at 18 months and 64 percent at
                                                                  24 months, which compares favorably to six
                                                                  comparable recent studies showing one-year
                                                                  survival rates of 52 percent and five comparable
                                                                  recent studies showing two-year survival of 33
                                                                  percent. Patients who received lower doses of
                                                                  TNFerade had lower risk of toxicity, while pathologic
                                                                  complete responses were achieved in 36 percent of
                                                                  resected patients who received the three highest
                                                                  doses. Study investigators concluded that TNFerade
                                                                  may reduce the rate of disease progression and
                                                                  recurrence in patients with locally advanced
                                                                  resectable esophageal cancer.
                                                                           January 27, 2006 GenVec, Inc. announced
                                                                  that Dr. Neil Senzer, Medical Director of the Mary
                                                                  Crowley Research Center, located in Dallas, Texas,
                                                                  presented long-term follow-up data on the Phase II
                                                                  study of GenVec's investigational oncology drug,
                                                                  TNFerade, at the American Society of Clinical
                                                                  Oncology's Gastroenterological Cancer Symposium
                                                                  in session in San Francisco. In oral and poster
                                                                  presentations, Dr. Senzer discussed results from a
                                                                  regimen in which 24 patients with locally advanced,
                                                                  resectable esophageal cancer were treated prior to
                                                                  surgery with chemotherapy, radiation, and
                                                                  TNFerade injections to the tumor in doses ranging
                                                                  from 4x10e8 p/u to 4x10e11 p/u.
                                                                           May 25, 2005 GenVec, Inc. announced that
                                                                  the FDA indicated clinical hold issues have been
                                                                  satisfactorily addressed for the rectal and
                                                                  esophageal indications and, as such, the clinical
                                                                  hold has been removed from the TNFerade IND.
                                                                  GenVec will resume the enrollment process for the
                                                                  Phase II rectal study. For the esophageal study, the
                                                                  patient accrual is completed and closed. Follow-up
                                                                  of the patients in the esophageal study is ongoing.
                                                                           October 7, 2004 GenVec announced that
                                                                  the U.S. Food and Drug Administration has
                                                                  requested that clinical trials of TNFerade be placed
                                                                  on clinical hold, pending review of information
                                                                  pertaining to a potential increase in the incidence of
                                                                  blood clots in patients with esophageal cancer who
                                                                  received the highest dose of TNFerade in a Phase II
                                                                  clinical trial. Interim results from this dose-escalation

GenVec Inc - Pipeline Report                                                                                             44

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  trial were reported by GenVec and presented at the
                                                                  European Organization for Research and Treatment
                                                                  of Cancer (EORTC) meeting in Geneva, Switzerland
                                                                  on October 1, 2004.
                                                                            November 14, 2002 GenVec, Inc announced
                                                                  the commencement of a Phase II clinical trial for its
                                                                  lead oncology product candidate, TNFerade, as part
                                                                  of first line therapy in patients with non-metastatic
                                                                  esophageal cancer. A total of approximately 55
                                                                  patients at 13 sites throughout the United States
                                                                  participate in the study. In the Phase II study,
                                                                  TNFerade added to the current standard of care
                                                                  (SOC), which is a chemotherapeutic regimen of
                                                                  cisplatin/5FU and radiation therapy followed by
                                                                  surgery. The primary endpoint complete tumor
                                                                  response, which determined through surgical
                                                                  removal and examination of the tumor tissue after
                                                                  TNFerade treatment is completed. The study has
                                                                  two separate parts; first, a dose-escalation Phase in
                                                                  which 3 different dose levels of TNFerade evaluated
                                                                  in combination with standard of care treatment. The
                                                                  highest, best-tolerated dose then selected from the
                                                                  first phase and used as the constant dose in the
                                                                  second phase of the study. TNFerade given
                                                                  endoscopically once weekly at the same time
                                                                  patients receive chemotherapy and radiation for up
                                                                  to 5 weeks prior to surgery.
                                                                            November 8, 2002 GenVec, Inc. announced
                                                                  that the final results from its Phase Ib clinical trial for
                                                                  its lead oncology product candidate, TNFerade.
                                                                            May 20, 2002 GenVec, Inc. announced the
                                                                  Phase Ib clinical trial data for its lead oncology
                                                                  product candidate, TNFerade. The results showed
                                                                  notable tumor shrinkage.
                                                                            April 10, 2002 GenVec, Inc. announced that
                                                                  it has completed patient accrual in its Phase Ib dose
                                                                  escalation trial for TNFerade in solid tumors. A total
                                                                  of 26 patients with solid tumors were enrolled at five
                                                                  separate dose levels. Tumors studied were from a
                                                                  variety of cancers including, but not limited to
                                                                  pancreatic, head and neck, rectal, colon, breast and
                                                                  lung cancer.
                                                                            November 6, 2001 GenVec , Inc. presented
                                                                  the first clinical trial data for its lead oncology
                                                                  product candidate, TNFerade. The interim Phase Ib
                                                                  clinical trial results were selected for oral
                                                                  presentation at the annual meeting of the American

GenVec Inc - Pipeline Report                                                                                               45

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                               Society of Therapeutic Radiology and Oncology
                                               meeting in San Francisco and were given by the
                                               University of Kentucky's Dr. Nader Hanna, one of
                                               the principal investigators.
                                                        February 15, 2001 GenVec, Inc. initiated
                                               Phase I clinical trials with TNFerade, a product
                                               candidate intended for use in combination with
                                               radiation therapy to improve the treatment of cancer.
                                               The preclinical studies demonstrated that TNFerade
                                               was well tolerated in animal experiments and
                                               appears to have a large therapeutic window.
Last Updated                                   11/6/2009
16 . TNFerade with Radiotherapy and Chemotherapy (First Line)
Product Type                                   Investigational drugs
Disease Hub                                    Cancer
Therapeutic Indication                         Pancreatic Cancer (Unresectable Locally Advanced
                                               Pancreatic Cancer (First Line Therapy))
Current Trial                                  III
Description                                    TNFerade is an adenovector, or DNA carrier, which
                                               contains the gene for tumor necrosis factor-alpha,
                                               golnerminogene pradenovec, with potent and well-
                                               documented anti-cancer effects, for direct injection
                                               into tumors. TNFerade, which is based on
                                               adenovector technology, stimulates the production
                                               of TNF-alpha in the tumor after the direct injection
                                               into the tumors. It enables the controlled production
                                               over a specific period of time of the TNF-alpha
                                               protein inside the tumor while avoiding unwanted
                                               exposure to healthy tissue. Fluorouracil is a
                                               fluorinated pyrimidine that acts as an antimetabolite
                                               antineoplastic agent. It acts by halting DNA
                                               synthesis and replication by inhibiting the enzyme
                                               thymidylate synthetase. Gemcitabine, an analog of
                                               deoxycytidine, is an antineoplastic anti-metabolite. It
                                               acts by inhibiting thymidylate synthetase, leading to
                                               inhibition of DNA synthesis and cell death.
                                               TNFerade is being developed with 5-FU/radiation
                                               therapy followed by gemcitabine or
                                               gemcitabine/erlotinib maintenance therapy.
                                               TNFerade in combination with Radiation and
                                               Chemotherapy is being developed as first-line
                                               intratumoral injection for the treatment of
                                               unresectable locally advanced pancreatic cancer.
Mechanism of Action                            ErbB1 Receptor Tyrosine Kinase
                                               Inhibitor;Ribonucleotide Reductase (RR)
                                               Inhibitor;Thymidylate Synthase (TS) Inhibitor;Tumor


GenVec Inc - Pipeline Report                                                                        46

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                         Necrosis Factor (TNF) Upregulator
Mode of Action                                                           Angiogenesis Inhibitor;Anticancer;DNA Repair
                                                                         Disrupter
                                                                   erlotinib
Chemical Name                                                            N-(3-ethynylphenyl)-6,7-bis(2-
                                                                         methoxyethoxy)quinazolin-4-amine
Chemical Structure




Molecular Weight                                                        393.441
Molecular Formula                                                       C22-H23-N3-O4
Molecule Type                                                           Small
Classification                                                          1) Chemical> Heterocyclic Compounds> >
                                                                        Heterocyclic Compounds, 2-Ring> > >
                                                                        Quinazolines
                                                                  Fluorouracil
Chemical Name                                                           5-fluoro-1H-pyrimidine-2,4-dione
Chemical Structure




Molecular Weight                                                        130.078
Molecular Formula                                                       C4-H3-F-N2-O2
Molecule Type                                                           Small
Classification                                                          1) Chemical> Heterocyclic Compounds> >
                                                                        Heterocyclic Compounds, 1-Ring> > > Pyrimidines
                                                                  gemcitabine
Chemical Name                                                           4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-
                                                                        (hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
                                                                        4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-
                                                                        (hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Chemical Structure




Molecular Weight                                                        263.2
Molecular Formula                                                       C9H11F2N3O4

GenVec Inc - Pipeline Report                                                                                            47

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Molecule Type                                                    Small
Classification                                                   1) Chemical> Nucleic Acids, Nucleotides, and
                                                                 Nucleosides> > Nucleosides> > >
                                                                 Deoxyribonucleosides> > > > Deoxycytidine
                                                                 2) Chemical> Nucleic Acids, Nucleotides, and
                                                                 Nucleosides> > Nucleosides> > > Pyrimidine
                                                                 Nucleosides> > > > Cytidine
                                                                 3) Chemical> Heterocyclic Compounds> >
                                                                 Heterocyclic Compounds, 1-Ring> > > Pyrimidines
                                                    golnerminogene pradenovec
Chemical Name                                                    DNA (synthetic human adenovirus 5 adenoviral
                                                                 vector AdGVEGR.TNF.11D)

Trial Details                                                     November 4, 2009 GenVec, Inc. announced that
                                                                  the U.S. Food and Drug Administration (FDA) has
                                                                  granted orphan drug designation to TNFerade for
                                                                  the treatment of pancreatic cancer.
                                                                           A randomized Phase II/III study of TNFerade
                                                                  Biologic in combination with 5-FU and radiation
                                                                  therapy for first-line treatment of unresectable locally
                                                                  advanced pancreatic cancer is ongoing. This trial
                                                                  compares TNFerade Biologic plus standard of care
                                                                  therapy (defined as infusion 5-FU and radiation
                                                                  therapy, followed by gemcitabine or
                                                                  gemcitabine/erlotinib maintenance therapy) versus
                                                                  standard of care therapy in the treatment of locally
                                                                  advanced, unresectable pancreatic cancer. Patients
                                                                  will be randomly selected (2:1) to one of the two
                                                                  treatment groups.
                                                                           Source: Company website
                                                                           August 6, 2009 GenVec, Inc. announced its
                                                                  financial results for the second quarter ended June
                                                                  30, 2009. As of July 31, 2009, 262 patients have
                                                                  been enrolled in the GenVec's pivotal PACT trial.
                                                                           June 1, 2009 GenVec presented the overall
                                                                  survival data in locally advanced pancreatic cancer
                                                                  patients treated with TNFerade in GenVec's ongoing
                                                                  Phase III Pancreatic Cancer Clinical Trial with
                                                                  TNFerade (PACT) at the 45th American Society of
                                                                  Clinical Oncology Annual Meeting in Orlando, FL.
                                                                  The poster, entitled "Multi-Center Randomized
                                                                  Controlled Phase III Clinical Trial using TNFerade
                                                                  with Chemoradiation in Patients with Locally
                                                                  Advanced Pancreatic Cancer: Interim Analysis of
                                                                  Overall Survival," reported on results of an interim
                                                                  analysis from the PACT trial. This interim analysis of


GenVec Inc - Pipeline Report                                                                                            48

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  overall survival was conducted after the 92nd death
                                                                  (one-third of total expected events) had occurred.
                                                                  The analysis concluded that TNFerade appeared to
                                                                  be safe and well-tolerated. The analysis also
                                                                  indicated a 25% reduction in the risk of death in the
                                                                  TNFerade plus standard-of-care (SOC) arm
                                                                  compared to the patients receiving SOC alone
                                                                  (Hazard Ratio = 0.75; 95% Confidence Interval
                                                                  [0.494 - 1.15]).
                                                                          November 19, 2008 GenVec announced
                                                                  top-line results of an interim analysis from its
                                                                  ongoing Phase III Pancreatic Cancer Clinical Trial
                                                                  with TNFerade (PACT study) in patients with locally
                                                                  advanced pancreatic cancer. GenVec's PACT trial is
                                                                  a multi-center, randomized, active, and controlled
                                                                  study of 330 patients designed to evaluate the safety
                                                                  and efficacy of TNFerade plus standard of care
                                                                  versus standard of care alone in patients with locally
                                                                  advanced pancreatic cancer. This interim analysis of
                                                                  overall survival, conducted after the 92nd death
                                                                  (one-third of total expected events), was designed to
                                                                  determine whether the study should continue and
                                                                  took place in the time frame originally estimated.
                                                                  Interim data demonstrated an approximately 25%
                                                                  lower risk of death in the TNFerade plus standard of
                                                                  care (SOC) arm relative to the SOC alone (Hazard
                                                                  Ratio= 0.753; 95% Confidence Interval [0.494-1.15]).
                                                                  An independent Data Safety Monitoring Board
                                                                  reviewed the interim analysis data and
                                                                  recommended the trial continue as planned. Kaplan-
                                                                  Meier analysis of data, based on this interim
                                                                  analysis, demonstrated that overall survival at 12
                                                                  months was 39.9% in the TNFerade plus SOC arm
                                                                  versus 22.5% in the SOC arm. Overall survival at 18
                                                                  months was 30.5% in the TNFerade plus SOC arm
                                                                  versus 11.3% in the SOC arm. At 24 months, overall
                                                                  survival was 10.6% in the TNFerade plus SOC arm
                                                                  versus 11.3% in the SOC arm. Median survival was
                                                                  9.9 months in both arms of the trial.
                                                                          November 10, 2008 GenVec announced that
                                                                  TNFerade has been granted Fast Track product
                                                                  designation by the U.S. Food and Drug
                                                                  Administration (FDA) for its proposed use in the
                                                                  treatment of locally advanced pancreatic cancer.
                                                                  The designation is based on GenVec having
                                                                  "provided evidence of the potential to improve
                                                                  survival in patients with pancreatic cancer".

GenVec Inc - Pipeline Report                                                                                          49

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                           April 15, 2008 GenVec, Inc presented
                                                                  preclinical data illustrating the activity of GenVec's
                                                                  lead product candidate, TNFerade, when used in
                                                                  combination with gemcitabine in preclinical models
                                                                  of pancreatic cancer at 98th Annual Meeting of the
                                                                  American Association of Cancer Research (AACR)
                                                                  in San Diego. GenVec presented a poster entitled
                                                                  "Combination of Human Tumor Necrosis Factor
                                                                  Alpha (hTNF-alpha) gene delivery with gemcitabine
                                                                  is effective in models of pancreatic cancer". Results
                                                                  of the research show that a combination of
                                                                  TNFerade and standard chemotherapy results in
                                                                  superior anti-tumor activity compared to
                                                                  chemotherapy alone.
                                                                           January 3, 2008 GenVec, Inc announced
                                                                  that it has reached agreement with the U.S. Food
                                                                  and Drug Administration to implement changes to
                                                                  the company's Phase II/III pancreatic cancer clinical
                                                                  trial (PACT study) with TNFerade in patients with
                                                                  locally advanced pancreatic cancer. FDA directed
                                                                  the company to measure overall survival as the
                                                                  primary efficacy endpoint, rather than 12-month
                                                                  survival. No increase in study size will be required,
                                                                  and a benefit in overall survival can be considered
                                                                  as a basis for full regulatory approval of TNFerade
                                                                  for this indication. The Company was asked to
                                                                  conduct two additional interim analyses of overall
                                                                  survival following one-third (92) and two-thirds (184)
                                                                  of the total events (deaths) for the study, with the
                                                                  potential to stop the trial if there is clear evidence of
                                                                  the drug's efficacy. The two interim analyses will be
                                                                  performed with minimal statistical penalties of 0.001
                                                                  and 0.004, respectively. The PACT trial, a multi-
                                                                  center randomized and controlled trial, is designed
                                                                  to evaluate the safety and efficacy of TNFerade plus
                                                                  standard of care versus standard of care alone in
                                                                  330 subjects with locally advanced pancreatic
                                                                  cancer. Chemotherapy and radiation are the current
                                                                  standard-of-care for treating this patient population.
                                                                  Patients in the trial are randomized in a 2:1 ratio to
                                                                  TNFerade plus standard therapy, or standard
                                                                  therapy alone.
                                                                           June 4, 2007 GenVec, Inc. announced that
                                                                  updated preliminary safety and efficacy data from
                                                                  the clinical development program of its lead product
                                                                  TNFerade was presented in a poster session on
                                                                  gastrointestinal cancers at the annual meeting of

GenVec Inc - Pipeline Report                                                                                             50

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  American Society for Clinical Oncology in Chicago,
                                                                  IL by Dr. The poster presentation, Multi-Center,
                                                                  Phase II/III, Randomized, Controlled Clinical Trial
                                                                  using TNFerade Gene Delivery Combined with
                                                                  Chemoradiation in Patients with Locally Advanced
                                                                  Pancreatic Cancer (LAPC), covered the most recent
                                                                  data from GenVec's Pancreatic Cancer Clinical Trial,
                                                                  known as the PACT study. This multi-center,
                                                                  randomized and controlled trial will evaluate the
                                                                  safety and efficacy of TNFerade plus standard of
                                                                  care, versus standard of care alone, in 330 subjects
                                                                  with locally advanced pancreatic cancer. The study
                                                                  is powered to detect a 20% absolute increase in the
                                                                  primary efficacy endpoint (12 month survival)
                                                                  compared to standard of care (SOC)
                                                                  chemoradiation. Patients are randomized in a 2:1
                                                                  ratio to TNFerade plus standard therapy, or standard
                                                                  therapy alone.
                                                                           January 11, 2007 GenVec, Inc. announced
                                                                  that it has reached agreement with the U.S. Food
                                                                  and Drug Administration to proceed with endoscopic
                                                                  ultrasound administration (EUS) of TNFerade as an
                                                                  additional option to percutaneous injection (PTA) for
                                                                  patients participating in its pivotal clinical trial for
                                                                  locally advanced pancreatic cancer (PACT).
                                                                  GenVec's PACT trial is a multi-center, randomized,
                                                                  active and controlled study targeted to enroll 330
                                                                  patients, designed to evaluate the safety and
                                                                  efficacy of TNFerade plus standard of care (SOC)
                                                                  versus standard of care alone in patients with locally
                                                                  advanced pancreatic cancer.
                                                                           December 19, 2006 GenVec, Inc.
                                                                  announced the initial interim efficacy analysis of
                                                                  survival data from its ongoing Phase II/III Pancreas
                                                                  Cancer Clinical Trial with TNFerade (PACT) in
                                                                  patients with locally advanced pancreatic cancer.
                                                                  The analysis was conducted as an initial component
                                                                  of a planned interim review of trial data by an
                                                                  independent data safety monitoring board (DMSB).
                                                                  Kaplan-Meier analysis of overall survival data, based
                                                                  on available results for the first 51 patients enrolled
                                                                  in the study, some followed for as long as 18
                                                                  months, showed a 42.5% absolute increase in
                                                                  overall survival with the addition of TNFerade to
                                                                  standard of care (SOC). At one year, survival was
                                                                  70.5% in the TNFerade + SOC arm, versus 28.0% in
                                                                  the SOC arm. Significance was at the 75%

GenVec Inc - Pipeline Report                                                                                            51

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  confidence interval level, and was based on 5
                                                                  deaths out of 33 TNFerade patients and 7 deaths
                                                                  out of 18 SOC patients.
                                                                             December 14, 2006 GenVec, Inc.
                                                                  announced that an independent data safety
                                                                  monitoring board (DSMB) has completed a planned
                                                                  interim analysis of safety data from the ongoing
                                                                  Phase II/III clinical trial with TNFerade in locally
                                                                  advanced pancreatic cancer. In addition to its
                                                                  recommendation that the trial continue, the DSMB
                                                                  supported the use of endoscopic ultrasonography
                                                                  (EUS) as an alternative to percutaneous tumor
                                                                  administration. GenVec has provided its interim
                                                                  safety data to the U.S. Food and Drug
                                                                  Administration and is waiting for final clearance to
                                                                  move forward with EUS administration. The Phase
                                                                  II/III clinical trial, known as PACT, is a multi-center,
                                                                  randomized and controlled study of 330 patients,
                                                                  designed to evaluate the safety and efficacy of
                                                                  TNFerade plus standard of care, versus standard of
                                                                  care alone (SOC) in patients with locally advanced
                                                                  pancreatic cancer. This interim evaluation was
                                                                  based on data from 40 patients, 25 of whom
                                                                  received standard of care plus TNFerade.
                                                                             Based on data from the Phase I and Phase II
                                                                  data in locally advanced, unresectable pancreatic
                                                                  cancer, GenVec is enrolling patients for a targeted
                                                                  330-patient randomized, controlled Phase II/III
                                                                  pivotal trial designed to assess safety and efficacy
                                                                  potential. The primary endpoint for this trial is overall
                                                                  survival at 12 months compared to standard of care.
                                                                             Source: SEC file: 10-Q (08/09/2006)
                                                                             March 15, 2006 GenVec, Inc. announced
                                                                  that it has received clearance from the U.S. Food
                                                                  and Drug Administration to expand its current Phase
                                                                  II clinical trial with TNFerade in locally advanced
                                                                  pancreatic cancer into a Phase II/III trial with a 12-
                                                                  month survival endpoint. Targeted enrollment will be
                                                                  expanded from 74 to 330 patients. The expanded
                                                                  Phase II/III trial will include additional study sites
                                                                  outside the United States. This expanded Phase II/III
                                                                  international multi-center trial will seek to enroll
                                                                  approximately 330 patients with locally advanced
                                                                  pancreatic cancer. Patients will be randomized two-
                                                                  to-one to receive chemotherapy (fluorouracil) and
                                                                  radiation therapy for five weeks, with or without a
                                                                  weekly intratumoral injection of TNFerade, followed

GenVec Inc - Pipeline Report                                                                                             52

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  by maintenance therapy (gemcitabine with or without
                                                                  Tarceva). The primary endpoint of the study will be
                                                                  overall survival at 12 months. GenVec is actively
                                                                  recruiting new study sites in the United States, India
                                                                  and Israel in addition to the U.S. sites that have
                                                                  been participating in the ongoing Phase II trial.
                                                                           February 11, 2005 GenVec, Inc. announced
                                                                  that it has received a letter from the U.S. Food and
                                                                  Drug Administration which allows the company to
                                                                  proceed with the randomized, controlled portion of
                                                                  the Phase II clinical trial of TNFerade in patients with
                                                                  locally advanced pancreatic cancer. This clinical
                                                                  study is designed to assess the clinical benefit of
                                                                  using TNFerade in combination with standard of
                                                                  care treatment in patients with this disease.
                                                                           In October 2004, the FDA placed the
                                                                  TNFerade clinical program on hold due to blood
                                                                  clots seen in patients with esophageal cancer in a
                                                                  separate Phase II trial. In response, GenVec
                                                                  submitted data to the FDA and requested
                                                                  permission to move forward only with the pancreatic
                                                                  cancer study. Other indications that were affected
                                                                  (esophageal and rectal cancer) remain on clinical
                                                                  hold. The 74-patient randomized, controlled portion
                                                                  of the Phase II study will assess the activity of
                                                                  TNFerade when administered concurrently with 5-
                                                                  flourouracil (5-FU) plus radiation followed by
                                                                  Gemcitabine, versus 5-FU plus radiation followed by
                                                                  Gemcitabine. Outcome measures will include
                                                                  progression- free survival at three months post-
                                                                  treatment, median survival, tumor resectability post-
                                                                  treatment, and objective tumor response.
                                                                           February 17, 2004 GenVec, Inc. announced
                                                                  the publication of positive results from a Phase I
                                                                  clinical trial of the Company's lead oncology product
                                                                  candidate, TNFerade, in the February 15, 2004
                                                                  issue of the Journal of Clinical Oncology. The trial
                                                                  demonstrated the use of TNFerade in combination
                                                                  with standard radiation therapy resulted in 21 of 30
                                                                  patients experiencing tumor shrinkage of 25% or
                                                                  more, a 70% objective response rate across 12
                                                                  different tumor types, as well as a positive safety
                                                                  profile.
                                                                           January 23, 2004 GenVec, Inc. presented
                                                                  new data on GenVec's lead oncology product
                                                                  candidate, TNFerade for pancreatic cancer, at the
                                                                  2004 ASCO Gastrointestinal Cancers Symposium

GenVec Inc - Pipeline Report                                                                                            53

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  held in San Francisco, California.
                                                                            June 2, 2003 GenVec, Inc announced
                                                                  preliminary data from the dose escalation portion of
                                                                  a Phase II study using TNFerade in combination
                                                                  with chemotherapy and radiation in patients with
                                                                  locally advanced, inoperable pancreatic cancer. The
                                                                  results presented on June 1st in a poster
                                                                  presentation at the American Society of Clinical
                                                                  Oncology (ASCO) Annual Meeting in Chicago,
                                                                  Illinois, indicated that TNFerade, when used in
                                                                  combination with standard chemotherapy and
                                                                  radiation, was well tolerated at the two dose levels
                                                                  evaluated to date.
                                                                            November 8, 2002 GenVec, Inc. announced
                                                                  the presentation of final results from its Phase Ib
                                                                  clinical trial of lead oncology product candidate,
                                                                  TNFerade, in patients with a variety of solid tumors
                                                                  at the American Society of Clinical Oncology
                                                                  (ASCO) Molecular Therapeutics Symposium in San
                                                                  Diego, California. The Phase Ib clinical trials of
                                                                  TNFerade were conducted at four centers around
                                                                  the country and involved patients with a wide variety
                                                                  of cancers including cancer of the pancreas, breast,
                                                                  lung, head and neck, skin, colon, and rectum.
                                                                            July 17, 2002 GenVec, Inc. announced the
                                                                  commencement of a randomized, controlled Phase
                                                                  IIb clinical trial for its lead cancer drug, TNFerade, in
                                                                  patients with locally advanced pancreatic cancer.
                                                                            April 10, 2002 GenVec, Inc. announced that
                                                                  it has completed patient accrual in its Phase Ib dose
                                                                  escalation trial for TNFerade in solid tumors. A total
                                                                  of 26 patients with solid tumors were enrolled at five
                                                                  separate dose levels. Tumors studied were from a
                                                                  variety of cancers including, but not limited to
                                                                  pancreatic, head and neck, rectal, colon, breast and
                                                                  lung cancer.
Last Updated                                                      11/5/2009
17 . BioBypass
Product Type                                                      Investigational drugs
Disease Hub                                                       Cardiovascular and Circulatory System
Therapeutic Indication                                            Coronary Artery Disease
Current Trial                                                     D
Description                                                       BioBypass is a cardiovascular product, which is
                                                                  intended to restore blood flow to areas of the heart
                                                                  with insufficient blood flow through the formation of
                                                                  new blood vessels, a process known as


GenVec Inc - Pipeline Report                                                                                              54

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  angiogenesis by delivering the therapeutic protein,
                                                                  vascular endothelial growth factor (VEGF121) that
                                                                  stimulates the growth of new blood vessels in heart
                                                                  tissue and restores blood flow to areas of the heart
                                                                  with poor blood flow. By directly injecting BioBypass
                                                                  into the heart wall through a minimally invasive
                                                                  catheter approach enables the sustained, controlled
                                                                  production of the VEGF121 protein in the area of the
                                                                  heart with poor blood flow. BioBypass was under
                                                                  development for the treatment of coronary artery
                                                                  disease.
Route of Administration                                           Parenteral
Mechanism of Action                                               Vascular Endothelial Growth Factor (VEGF)
                                                                  Upregulator
Mode of Action                                                    Angiogenesis Inducer
Trial Details                                                     In October 2008, GenVec, Inc. completed its
                                                                  collaboration agreement with the Cordis Corporation
                                                                  (Cordis). As of December 31, 2008, all activities and
                                                                  cost reimbursements associated with this agreement
                                                                  and with the previously announced decision in May
                                                                  2006 to end the Phase II BIOBYPASS trial have
                                                                  been completed.
                                                                           Source: SEC File: 10-K (2008).
                                                                           BioBypass angiogen is in Phase II clinical
                                                                  trials for the treatment of Coronary Artery Disease.
                                                                           Source: SEC File: 10-K (3/17/2008)
                                                                           May 10, 2006 GenVec announced that it is
                                                                  focusing its resources on its lead cancer drug and
                                                                  has decided to stop enrolling patients in a Phase II
                                                                  trial testing the company's drug for treating severe
                                                                  coronary artery disease. The company says patients
                                                                  already enrolled in the Phase II study of the heart
                                                                  drug, called BioBypass, will complete follow up and
                                                                  data will be collected and analyzed in accordance
                                                                  with the research agreement between GenVec and
                                                                  its collaborator, Cordis Corp. a Miami-based medical
                                                                  device maker.
                                                                           March 2, 2005 GenVec, Inc. announced the
                                                                  launch of a Phase IIB randomized, placebo-
                                                                  controlled trial of its Biobypass angiogen for the
                                                                  treatment of severe coronary artery disease. The
                                                                  NOVA (NOGA Delivery of VEGF for Angina) trial will
                                                                  evaluate the effects of Biobypass on exercise
                                                                  tolerance, heart function, symptoms and quality of
                                                                  life in approximately 129 patients suffering from
                                                                  moderate to severe chest pain due to advanced
                                                                  coronary artery disease.

GenVec Inc - Pipeline Report                                                                                         55

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                            November 20, 2002 GenVec Inc said that a
                                                                  Phase II clinical study of Biobypass angiogen shows
                                                                  significant positive results in patients with severe
                                                                  artery disease. The data were presented in a Late
                                                                  Breaking Session of the 75th Scientific Sessions of
                                                                  the American Heart Association in Chicago. The
                                                                  Phase II Biobypass clinical trial, called the REVASC
                                                                  trial, involved 20 sites in North America and 71
                                                                  patients with severe coronaryartery disease were
                                                                  enrolled. It is the largest, randomized, controlled
                                                                  study reported to date with intramyocardial injection
                                                                  of genes coding for angiogenic growth factor. The
                                                                  REVASC study was designed to explore the safety
                                                                  and efficacy of Biobypass in patients with severe
                                                                  coronary artery disease. The primary analysis
                                                                  showed a trend towards improvement in the
                                                                  Biobypass group in ST segment depression at 3
                                                                  months (primary endpoint) of 24 seconds (p=0.35)
                                                                  which improved to 1.1 minutes (28% increase over
                                                                  baseline) at 6 months which was a statistically
                                                                  significant difference from the control group
                                                                  (p=0.024). There were significant improvements in
                                                                  total time to chest pain on the treadmill and total
                                                                  exercise time on the treadmill at both 3 and 6
                                                                  months. For example, at 6 months post treatment,
                                                                  the time to angina increased by 1.5 minutes from
                                                                  baseline, corresponding to a 37% increase in the
                                                                  Biobypass group as compared to the control group,
                                                                  which was unchanged (p=0.002). These endpoints
                                                                  are widely accepted as a measure of patient benefit.
                                                                  Significant improvements in patient quality of life
                                                                  were were seen at 6, 12 and 26 weeks as assessed
                                                                  by the Seattle Angina Questionnaire. Measures of
                                                                  these improvements included the patient's ability to
                                                                  get dressed, to resume play with their children or
                                                                  grandchildren, and a reduced need for
                                                                  cardiovascular medications. The magnitude of
                                                                  improvement seen was similar to what has been
                                                                  observed after angioplasty. Significant
                                                                  improvements in patient function were also
                                                                  assessed by healthcare professionals through the
                                                                  Canadian Cardiovascular Society Angina Class
                                                                  Questionnaire. Again, significant improvements were
                                                                  seen at 6, 12 and 26 weeks. Continuous
                                                                  improvements from 3 to 6 months were consistently
                                                                  seen across all of these endpoints. Biobypass was
                                                                  well tolerated and there was no difference in serious

GenVec Inc - Pipeline Report                                                                                         56

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                adverse events noted between the Biobypass group
                                                and the control group.
                                                          May 1, 2002 GenVec, Inc. announced the
                                                completion of patient accrual in the Phase II clinical
                                                trial of its lead cardiovascular product candidate,
                                                BioBypass angiogen, in coronary artery disease.
                                                          April 26, 2000 GenVec, Inc. announced that
                                                a randomized Phase II clinical study has begun with
                                                Biobypass angiogenic agent, a new experimental
                                                product designed to treat coronary artery disease
                                                and peripheral vascular disease. Patients will be
                                                randomly allocated to receive either Biobypass
                                                angiogenic agent through a minimally invasive
                                                surgical procedure or best medical practice.
Last Updated                                    9/1/2009
Partnering Details                              1/8/2004 -- GenVec entered into a research
                                                collaboration with the Cordis Cardiology Division of
                                                Cordis Corporation, a Johnson & Johnson company,
                                                to study the clinical benefit of BIOBYPASS in a
                                                procedure involving guided delivery of the
                                                angiogenic agent directly into targeted regions of the
                                                heart in patients with severe coronary artery disease
                                                using the Cordis NOGASTAR Mapping Catheter and
                                                MYOSTAR Injection Catheter.
18 . Myoblast Cell Transplantation Therapy GENVEC
Product Type                                    Investigational drugs
Disease Hub                                     Cardiovascular and Circulatory System
Therapeutic Indication                          Congestive Heart Failure
Current Trial                                   D
Description                                     Myoblast Cell Transplantation Therapy includes
                                                isolation of Human Muscle Cells and use of these
                                                cells for transplantation into damaged heart muscle.
                                                These cells would be isolated from a muscle biopsy
                                                who had suffered a heart attack, thereby allowing
                                                transplantation of the muscle cells into heart, which
                                                would avoid any rejection by the immune system.
                                                Myoblast Cell Transplantation Therapy was under
                                                development for the treatment of congestive heart
                                                failure.
Mechanism of Action                             Not Applicable
Trial Details                                   December 29, 2005 GenVec, Inc. announced the
                                                sale of its myoblast cell therapy program to Mytogen,
                                                Inc., a newly-formed private biotechnology company
                                                specializing in the development of cell therapy
                                                products, in exchange for potential future milestone
                                                and royalty payments to GenVec.


GenVec Inc - Pipeline Report                                                                        57

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                           March 8, 2005 GenVec, Inc. announced that
                                                                  three year follow-up data from a Phase I study of its
                                                                  myoblast cell transplantation therapy for congestive
                                                                  heart failure were presented at the 2005 American
                                                                  College of Cardiology 54th Annual Scientific Session
                                                                  in Orlando, Florida. The purpose of this multicenter
                                                                  study was to demonstrate the safety and feasibility
                                                                  of using autologous myoblast transplantation to
                                                                  repair damaged heart tissue in patients who have
                                                                  suffered a heart attack. In the study, myoblasts were
                                                                  harvested from the leg muscles of 30 patients and
                                                                  then cultured using GenVec's proprietary technique.
                                                                  Twenty-four patients received escalating doses of
                                                                  each patient's own purified myoblasts, which were
                                                                  injected into the area of the heart scarred by
                                                                  previous myocardial infarction during a previously
                                                                  scheduled coronary artery bypass surgery.
                                                                  Additionally, 6 patients scheduled to have Left
                                                                  Ventricular Assist Device (LVAD) implantation as a
                                                                  bridge to heart transplant received cells at the time
                                                                  of LVAD surgery.
                                                                           November 8, 2004 GenVec, Inc. announced
                                                                  Positive findings from three studies assessing the
                                                                  safety of using muscle precursor cells (myoblasts) to
                                                                  treat severe congestive heart failure. In this new
                                                                  approach, which seeks to repair heart muscle
                                                                  damaged after a heart attack, myoblasts are taken
                                                                  from the leg muscles of patients with congestive
                                                                  heart failure, cultured using a proprietary technique,
                                                                  and then transplanted into the scar tissue in the
                                                                  heart. Each patient receives myoblast transplants
                                                                  derived from the cells taken from his or her own
                                                                  body to help avoid an immune response.
                                                                           November 12, 2003 GenVec, Inc.
                                                                  announced the presentation of Phase I safety data
                                                                  for its myocardial infarction and congestive heart
                                                                  failure product candidate, myoblast cell
                                                                  transplantation. Positive safety data on twenty-seven
                                                                  patients in three Phase I studies reported. The
                                                                  results indicate that these patients had not
                                                                  experienced an increased frequency of arrhythmia
                                                                  compared to patients not undergoing cell
                                                                  transplantation. Improved cardiac function, based on
                                                                  echocardiography (ultrasound of the heart), was
                                                                  reported in patients receiving myoblast cell
                                                                  transplantation in combination with coronary artery
                                                                  bypass graft (CABG). Myoblast cell transplantation

GenVec Inc - Pipeline Report                                                                                          58

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                    uses the patient's own muscle cells to attempt to
                                                                    repair heart muscle damaged after a heart attack.
                                                                            November 14, 2002 Preliminary data from
                                                                    two Diacrin-sponsored Phase I clinical trials using
                                                                    human muscle cells for cardiac repair will be
                                                                    presented during the American Heart Association's
                                                                    Scientific Sessions 2002 in Chicago, Illinois.
                                                                            In August 2000, Diacrin Inc initiated a six-
                                                                    patient, Phase I clinical trial for patients with
                                                                    damaged heart muscle at Temple University
                                                                    Hospital.
Last Updated                                                        8/25/2009
19 . TNFerade
Product Type                                                     Investigational drugs
Disease Hub                                                      Cancer
Therapeutic Indication                                           Melanoma
Current Trial                                                    D
Description                                                      TNFerade is an adenovector, or DNA carrier, which
                                                                 contains the gene for tumor necrosis factor-alpha,
                                                                 golnerminogene pradenovec, with potent and well-
                                                                 documented anti-cancer effects, for direct injection
                                                                 into tumors. TNFerade, which is based on
                                                                 adenovector technology, stimulates the production
                                                                 of TNF-alpha in the tumor after the direct injection
                                                                 into the tumors. It enables the controlled production
                                                                 over a specific period of time of the TNF-alpha
                                                                 protein inside the tumor while avoiding unwanted
                                                                 exposure to healthy tissue. TNFerade was under
                                                                 development for the treatment of melanoma.
Route of Administration                                          Intratumor
Mechanism of Action                                              Tumor Necrosis Factor (TNF) Upregulator
Mode of Action                                                   Anticancer
                                                    golnerminogene pradenovec
Chemical Name                                                    DNA (synthetic human adenovirus 5 adenoviral
                                                                 vector AdGVEGR.TNF.11D)

Trial Details                                                       GenVec has opted to suspend the Metastatic
                                                                    Melanoma program for TNFerade to dedicate
                                                                    resources towards other indications.
                                                                            Souce: SEC File: 10-K(16/3/2009)
                                                                            GenVec's TNFerade is in Phase II clinical
                                                                    development for the treatment of Melanoma.
                                                                            Source: SEC File: 10-K (3/17/2008)
                                                                            April 4, 2006 GenVec, Inc. reported
                                                                    preclinical findings showing that TNFerade inhibited
                                                                    metastasis of melanoma tumors in an animal model


GenVec Inc - Pipeline Report                                                                                               59

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  of this disease. The findings were presented at the
                                                                  annual meeting of the American Association for
                                                                  Cancer Research in Washington. Based upon
                                                                  previous results from a Phase I study in which three
                                                                  out of three advanced melanoma patients with solid
                                                                  tumors had complete responses to TNFerade plus
                                                                  radiation therapy, GenVec scientists developed a
                                                                  mouse model to test whether and how intratumoral
                                                                  injections of TNFerade could impact melanoma
                                                                  metastasis. The study results showed that direct
                                                                  injection of TNFerade into melanoma tumors
                                                                  decreased tumor size and reduced lymphatic
                                                                  metastasis outside the treatment area.
                                                                           March 29, 2006 GenVec, Inc. announced
                                                                  that it has begun a Phase II clinical study to evaluate
                                                                  the anticancer activity of TNFerade in patients with
                                                                  metastatic melanoma. The open-label, single-arm,
                                                                  multi-center study will assess tumor response after
                                                                  four weeks of intratumoral injections of TNFerade
                                                                  plus concomitant radiation therapy in 29 patients
                                                                  with stage III or IV metastatic melanoma who are
                                                                  ineligible for curative surgery or unlikely to benefit
                                                                  from other treatment options. Patients will be
                                                                  evaluated two months after the completion of
                                                                  therapy and followed for three years thereafter.
                                                                           April 20, 2005 GenVec, Inc. announced the
                                                                  presentation of two posters at the American
                                                                  Association for Cancer Research (AACR) in
                                                                  Anaheim, California. The first poster, "Local Therapy
                                                                  with TNFerade and Radiation Suppresses
                                                                  Metastatic Disease in the Spontaneously Metastatic
                                                                  B16F10 Melanoma Model," showed that TNFerade
                                                                  significantly reduced the spread (metastasis) of the
                                                                  cancer to lymph nodes in a mouse model of
                                                                  melanoma.
Last Updated                                                      8/28/2009
20 . TNFerade
Product Type                                                      Investigational drugs
Disease Hub                                                       Cancer
Therapeutic Indication                                            Sarcoma (Soft Tissue Sarcoma)
Current Trial                                                     D
Description                                                       TNFerade is an adenovector, or DNA carrier, which
                                                                  contains the gene for tumor necrosis factor-alpha,
                                                                  golnerminogene pradenovec, with potent and well-
                                                                  documented anti-cancer effects, for direct injection
                                                                  into tumors. TNFerade, which is based on


GenVec Inc - Pipeline Report                                                                                           60

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                 adenovector technology, stimulates the production
                                                                 of TNF-alpha in the tumor after the direct injection
                                                                 into the tumors. It enables the controlled production
                                                                 over a specific period of time of the TNF-alpha
                                                                 protein inside the tumor while avoiding unwanted
                                                                 exposure to healthy tissue. TNFerade was under
                                                                 development for the treatment of soft tissue
                                                                 sarcoma.
Route of Administration                                          Intratumor
Mechanism of Action                                              Tumor Necrosis Factor (TNF) Upregulator
Mode of Action                                                   Anticancer
                                                    golnerminogene pradenovec
Chemical Name                                                    DNA (synthetic human adenovirus 5 adenoviral
                                                                 vector AdGVEGR.TNF.11D)

Trial Details                                                       In October 2004, the FDA placed the TNFerade
                                                                    clinical program on hold due to blood clots seen in
                                                                    patients with esophageal cancer in the dose
                                                                    escalating portion of the esophageal Phase II trial. In
                                                                    response, GenVec submitted data to the FDA and
                                                                    requested permission to move forward only with the
                                                                    pancreatic study. GenVec have not yet requested
                                                                    permission to move forward with other indications
                                                                    and the other two studies affected by the clinical
                                                                    hold.
                                                                             September 10, 2004 GenVec, Inc.
                                                                    announced that results from a Phase I study for its
                                                                    lead product candidate, TNFerade, in patients with
                                                                    soft tissue sarcoma of the extremities were
                                                                    published in the edition of Clinical Cancer Research.
                                                                             February 17, 2004 GenVec, Inc. announced
                                                                    the publication of positive results from a Phase I
                                                                    clinical trial of the Company's lead oncology product
                                                                    candidate, TNFerade, in the February 15, 2004
                                                                    issue of the Journal of Clinical Oncology. The trial
                                                                    demonstrated the use of TNFerade in combination
                                                                    with standard radiation therapy resulted in 21 of 30
                                                                    patients experiencing tumor shrinkage of 25% or
                                                                    more, a 70% objective response rate across 12
                                                                    different tumor types, as well as a positive safety
                                                                    profile.
                                                                             June 2, 2003 GenVec, Inc. announced data
                                                                    from a Phase I clinical trial using TNFerade in
                                                                    combination with radiation therapy inpatients with
                                                                    soft tissue sarcoma. The results presented in a
                                                                    poster presentation at the American Society of


GenVec Inc - Pipeline Report                                                                                             61

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  Clinical Oncology (ASCO) AnnualMeeting in
                                                                  Chicago, Illinois, demonstrated that TNFerade was
                                                                  well tolerated with no dose limiting toxicity reported.
                                                                  Objective responses were seen in 11of 13 (85%)
                                                                  evaluable patients. Two patients experienced a
                                                                  complete response and 9 patients had partial
                                                                  responses. Objective responses were seen in all 6
                                                                  evaluable patients treated with the highest dose of
                                                                  TNFerade. The tumors treated were generally very
                                                                  large and typically do not respond well to standard
                                                                  radiation therapy.
                                                                           November 25, 2002 GenVec Inc said that
                                                                  preliminary Phase I trial data suggests the
                                                                  company's TNFerade was well tolerated as a
                                                                  treatment of soft tissue sarcoma, which is a rare
                                                                  form of cancer. A total of 14 patients will receive the
                                                                  investigational gene-based therapy at leading
                                                                  cancer centers in the United States. Data from the
                                                                  first two groups, or 7 patients, were presented
                                                                  November 22, 2002 at the 14th EORTC-NCI-AACR
                                                                  Symposium "Molecular Targets and Cancer
                                                                  Therapeutics" in Frankfurt, Germany. The Phase I
                                                                  study was designed as a dose-escalation safety
                                                                  study testing three doses of TNFerade in patients
                                                                  with soft tissue sarcoma of the extremity. These are
                                                                  generally very large tumors that typically do not
                                                                  respond well to standard therapies. Patients were
                                                                  already scheduled to receive radiation therapy for
                                                                  one of two reasons (a) before surgery to reduce the
                                                                  tumor size or (b) for palliation, to reduce symptoms
                                                                  in patients who cannot undergo surgery to remove
                                                                  the tumor. TNFerade was well tolerated with no
                                                                  dose-limiting toxicities reported. Maximum tolerated
                                                                  dose was not reached. Although this study was
                                                                  designed to test the safety of three dose levels of
                                                                  TNFerade in patients with soft tissue sarcoma,
                                                                  evidence of activity on the tumors was also reported.
                                                                  TNFerade treatment plus radiation therapy resulted
                                                                  in an overall objective tumor response rate of 71%
                                                                  (5 out of 7 patients). Objective tumor response rate
                                                                  means that these patients experienced tumor
                                                                  shrinkage between 50% and 100%. Two of 7
                                                                  patients (29%) experienced a complete response
                                                                  (CR), which is 100% tumor eradication. These
                                                                  patients had very large tumors, (3-4 liters), or
                                                                  roughly the size of a watermelon. Three of seven
                                                                  patients (43%) experienced a partial response (PR),

GenVec Inc - Pipeline Report                                                                                           62

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  which is tumor shrinkage between 50-99%. One
                                                                  patient had stable disease which means that the
                                                                  tumor size did not change significantly from
                                                                  baseline. One patient had progressive disease,
                                                                  which means their tumor grew more than 25%.
                                                                  Clinicians also noted that CT scans, often used to
                                                                  measure the size of the tumors after treatment,
                                                                  actually underestimated the response rate as
                                                                  compared to the actual tumor response noted on
                                                                  pathological (laboratory) review after surgical
                                                                  removal of the tumor.
                                                                            September 24, 2002 GenVec, Inc.
                                                                  announced that it has completed patient accrual in
                                                                  the Phase I study of its lead oncology product
                                                                  candidate, TNFerade, in patients with soft tissue
                                                                  sarcoma of the extremities. A total of 14 patients
                                                                  were enrolled in the study conducted at five clinical
                                                                  trial sites throughout the United States.
Last Updated                                                      11/19/2009
21 . BioBypass
Product Type                                                      Investigational drugs
Disease Hub                                                       Cardiovascular and Circulatory System
Therapeutic Indication                                            Peripheral Vascular Disease (Peripheral Arterial
                                                                  Disease)
Current Trial                                                     F
Description                                                       BioBypass is intended to restore blood flow to areas
                                                                  of the heart with insufficient blood flow through the
                                                                  formation of new blood vessels, a process known as
                                                                  angiogenesis. BioBypass produces the therapeutic
                                                                  protein, vascular endothelial growth factor
                                                                  (VEGF121) that stimulates the growth of new blood
                                                                  vessels in heart tissue and restores blood flow to
                                                                  areas of the heart with poor blood flow. By directly
                                                                  injecting BioBypass into the heart wall through a
                                                                  minimally invasive catheter approach enables the
                                                                  sustained, controlled production of the VEGF121
                                                                  protein in the area of the heart with poor blood flow.
                                                                  BioBypass was under development for the treatment
                                                                  of peripheral arterial disease.
Route of Administration                                           Parenteral
Mechanism of Action                                               Vascular Endothelial Growth Factor (VEGF)
                                                                  Upregulator
Mode of Action                                                    Angiogenesis Inducer
Trial Details                                                     January 7, 2003 GenVec, Inc. announced top line
                                                                  findings from a Phase II study with its product
                                                                  candidate for the treatment of poor blood flow in the


GenVec Inc - Pipeline Report                                                                                              63

© Life Science Analytics, Inc. 2010 (published January 04,2010)
                                                                  legs, also known as Peripheral Arterial Disease, or
                                                                  PAD. In the randomized, placebo-controlled study,
                                                                  patients treated with GenVec's investigational drug
                                                                  candidate, BioBypass-PAD, did not benefit
                                                                  significantly more than patients receiving a placebo
                                                                  on any of the primary and secondary clinical
                                                                  endpoints. This 107-patient, Phase II clinical trial of
                                                                  BioBypass-PAD was conducted in 20 clinical sites
                                                                  throughout the United States.
                                                                            May 30, 2002 GenVec, Inc. announced the
                                                                  completion of patient accrual in the Phase II clinical
                                                                  trial of its lead cardiovascular product candidate,
                                                                  BioBypass angiogen, in peripheral vascular disease.
                                                                            November 13, 2001 GenVec Inc. announced
                                                                  the final results from its Phase I study with
                                                                  BioBypass in patients with peripheral vascular
                                                                  disease (PVD), the progressive narrowing of blood
                                                                  vessels in the legs. The Phase I study was an open-
                                                                  labeled dose escalating study in a total of 33
                                                                  patients with severe debilitating peripheral vascular
                                                                  disease. The study, which was primarily a safety
                                                                  study, demonstrated that BioBypass, given by 20
                                                                  intramuscular injections in and around the area in
                                                                  need of new blood vessels was well tolerated with
                                                                  injection site swelling being the only consistently
                                                                  recorded drug-related side effect. Although this was
                                                                  a Phase I study, early indications of biologic activity
                                                                  were observed. The Absolute Claudication Distance
                                                                  (ACD), which is the distance a patient can walk on a
                                                                  treadmill before being forced to stop due to leg pain,
                                                                  trended upward in the patients in whom it was
                                                                  measured. Following treatment, the mean
                                                                  improvement was 1.2 minutes at 30 days, 1.9
                                                                  minutes at 3 months, 2.6 minutes at 6 months, and
                                                                  4.9 minutes at 12 months (~77% improvement). The
                                                                  ACD is the endpoint, which would typically be used
                                                                  by the FDA to assess clinical benefit. An increase in
                                                                  quality of life (QOL) as estimated by a Walking
                                                                  Impairment Questionaire, a questionnaire which
                                                                  assesses to what extent improvements in walking
                                                                  results in improvements of QOL was also seen.
                                                                            August 10, 2000 GenVec, Inc. announced
                                                                  that Phase II human clinical trials have begun with
                                                                  BioBypass angiogenic agent in patients with
                                                                  peripheral vascular disease (PVD), the progressive
                                                                  narrowing of blood vessels in the legs.
Last Updated                                                      9/1/2009

GenVec Inc - Pipeline Report                                                                                           64

© Life Science Analytics, Inc. 2010 (published January 04,2010)
* Source: MedTRACK




GenVec Inc - Pipeline Report                                      65

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Recent Updates
The following are company news stories and updates from the previous three months.

Company Announcements

10/16/2009 -- StockPreacher.com Issues Trading Outlook for GenVec Inc.
       On October 16, 2009 StockPreacher.com announced an investment report featuring anti-cancer
drug developer GenVec Inc. The report includes financial and investment analysis, analyst consensus, and
pertinent industry information you need to know to make an educated investment decision.
* Source: MedTRACK




GenVec Inc - Pipeline Report                                                                           66

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Deals & Alliances

11/5/2009 -- GenVec Signs New Contract to Support HIV and Influenza Vaccine Development
       On November 5, 2009 GenVec, Inc. announced that SAIC-Frederick, Inc. has signed a contract with
GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center
(VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of
Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over
the next year, GenVec will receive approximately $2.6 million. Under the contract, the vaccines would be
comprised of genetic material supplied by the VRC and adenoviral vectors supplied by GenVec.
* Source: MedTRACK




GenVec Inc - Pipeline Report                                                                                67

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Regulatory

11/4/2009 -- FDA Grants Orphan Drug Designation for TNFerade
       On November 4, 2009 GenVec, Inc. announced that the U.S. Food and Drug Administration (FDA)
has granted orphan drug designation to TNFerade for the treatment of pancreatic cancer.
* Source: MedTRACK




GenVec Inc - Pipeline Report                                                                         68

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Clinical Trial Classification and Product Counts
Product Counts : “Unique Products” vs. “Product Records”

 Within MedTRACK, a unique product can have multiple records due to its development in multiple
indications, its involvement in deals and alliances between multiple parties, and its ownership by a
subsidiary or operating company of a larger entity. Within MedTRACK and LSA reports, then, multiple
records for a product will appear, and will be reflected in summary counts, under the following scenarios:

•   If a product is in development in, or on the market for treatment for, multiple indications, then a separate
    record for the product will exist under each indication.
•   If a product is partnered, then a record for the product will exist for each party involved in the
    partnership.
•   If a product is assigned to a company that is a subsidiary or operating company with a Web site
    separate from its parent company, then records for the product will exist in both the subsidiary/operating
    company and in the parent company.


 Combination products and reformulations, however, will be listed as separate unique products, subject to
the rules listed above for multiple records.

Partnered vs. Unpartnered Products

 When a product within MedTRACK is involved in a deal between two or more parties, a record for the
product will appear in the pipeline of each party involved in the deal and the product will be designated as
“Partnered.” All deals will qualify a product as “Partnered” with the following exceptions:

•    Infringement
•    Manufacturing
•    Miscellaneous
•    Option
•    Sales Settlement
•    Spin - Off
•    Supply Termination




GenVec Inc - Pipeline Report                                                                                   69

© Life Science Analytics, Inc. 2010 (published January 04,2010)
GENERAL PRINCIPLES FOR TRIAL PHASES IN MEDTRACK AND LSA REPORTS

Updating Trial Phases:

MedTRACK updates a product’s trial phase whenever the following occurs:

•   Recruitment / Enrolment of patients/volunteers.
•   Screening of patients/volunteers.
•   Initiated patient dosing.
•   The trial phase is updated in the company Web site, SEC filing, or clinicaltrials.gov Web site without any
    announcements.

Lifecycle Management:

If a company begins clinical trials to test the effectiveness of a marketed product in another indication,
MedTRACK will create a separate record for the product and list it as in Phase II of the new indication.

Territorial Variations in Trial Phase:

Products whose trial phase varies by country or territory are classified using the following rules:

•   If a product is available in the US in one particular trial phase for a particular indication and the same
    product is available in a different trial phase for the same indication in other countries, then MedTRACK
    will list the product’s US trial phase.
•   For public companies, if a product has no information regarding its trial phase in the US for a particular
    indication, MedTRACK will report a product’s trial phase in another specific country, with a preference
    given to Europe, then Japan, and then other countries.
•   For private companies, if a product has no information regarding its trial phase in the US for a particular
    indication, then MedTRACK will report the trial phase for the particular country where the trial is being
    conducted or the product marketed.

Non-Approval Letters:

If, after receiving a non-approvable letter from the FDA, a company intends to file again for approval by
conducting additional trials, then a product’s active phase will serve as its trial phase in MedTRACK.




GenVec Inc - Pipeline Report                                                                                  70

© Life Science Analytics, Inc. 2010 (published January 04,2010)
Notes on Specific Trial Phases

NA (Not Available / Research Stage) will include the following:

•   Products for which there is some trial information but no exact trial phase available.
•   Products that are in lead optimization, discovery, or before the preclinical stage.
•   Products that have been rejected by the FDA or had their NDA withdrawn, but whose trial information
    does not mention a current trial phase.

PA (Pending Approval) will include the following:

•   Products that receive approvable letter from the FDA
•   Products that receive Priority Review Designation
•   Tentatively approved products
•   Products for which the FDA has accepted an NDA/ANDA filing.
•   Products whose company is in discussions with the FDA regarding approval following the rejection of an
    NDA/ANDA.
•   Products that have been submitted in European Medicines Agency (EMEA) for Marketing Authorization
    Application (MAA) or in that case to any regulatory authorities in any particular country, if the product’s
    active ingredient (with or without trade name) is not under development in the US.

M (Marketed) will include the following:

•   All products listed as in market by company Web sites, SEC files regarding the launch date, FDA Web
    site, or any other relevant Web links and information resources.
•   Approved products for which no information regarding milestones and/or launch date has appeared six
    months after the approval date.

PM (Post-Marketing Trials) will include the following:

•   Marketed products that are under ongoing Phase IV or Post marketing surveillance clinical trials. Once
    phase IV trials are completed, products are reclassified as M.

D (Discontinued) will include the following:

•    Products whose discontinuation is confirmable through press releases, SEC filings, company Web sites,
     the FDA site, competitor Web sites, or another reliable source.
•    Products for which, after being rejected by the FDA, there is no information regarding additional trials for
     two or more years.
•    Products whose company has withdrawn the NDA and provided no information regarding additional
     trials for two or more years.
•    Products, in any phase, for which there is no news or information from press releases, company Web
     sites, SEC filings, the FDA site, competitor Web sites, or another reliable source for more than two
     years.



GenVec Inc - Pipeline Report                                                                                   71

© Life Science Analytics, Inc. 2010 (published January 04,2010)
F (Failed) will include the following:

•    All products that cannot meet the endpoint of their trial or whose trial information labels them failed.


For a free demonstration and trial use of the MedTRACK database, contact Life Science Analytics
at 570-504-1400, or by email at info@medtrack.com.




GenVec Inc - Pipeline Report                                                                                    72

© Life Science Analytics, Inc. 2010 (published January 04,2010)

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:2910
posted:3/15/2010
language:English
pages:72